

Edgar Filing: ACETO CORP - Form 10-K/A

ACETO CORP  
Form 10-K/A  
October 21, 2003

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 10-K/A

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended JUNE 30, 2003  
-----

Commission file number 0-4217  
-----

ACETO CORPORATION  
-----

(Exact name of the registrant specified in its charter)

|  |  |
|--|--|
| New York<br>-----<br>(State or other jurisdiction of<br>incorporation or organization)       | 11-1720520<br>-----<br>(I.R.S. Employer<br>Identification No.) |
| One Hollow Lane, Lake Success, New York<br>-----<br>(Address of principal executive offices) | 11042<br>-----<br>(Zip Code)                                   |

Registrant's telephone number, including area code: (516) 627-6000

Registrant's website address: www.aceto.com  
-----

Securities registered pursuant to Section 12 (b) of the Act: None

Securities registered pursuant to Section 12 (g) of the Act:

Common Stock, par value \$.01 per share  
-----

(Title of Class)

Name of each exchange on which registered: The Nasdaq National Market.

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the company was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No   
-----

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any

## Edgar Filing: ACETO CORP - Form 10-K/A

amendment to this Form 10-K. [X]

Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes  No   
-----

The aggregate market value of the voting stock of the Company held by non-affiliates of the Company as of September 19, 2003 was approximately \$156,200,708.

The Registrant has 10,337,050 shares of common stock outstanding as of September 19, 2003.

Documents incorporated by reference: The information required in response to Part III of this Annual Report on Form 10-K is hereby incorporated by reference to the specified portions of the Registrant's definitive proxy statement for the Annual Meeting of Shareholders to be held on December 4, 2003.

### EXPLANATORY NOTE

This Amendment No. 1 to our Annual Report on Form 10-K for the fiscal year ended June 30, 2003 filed with the Commission on September 26, 2003 is being filed for the sole purpose of correcting certain information contained in Item 6: Selected Financial Data that was not appropriately adjusted for the Company's 3-for-2 split in the form of a 50 percent common stock dividend declared in December 2002. Specifically, our Form 10-K is hereby amended to state correctly in Item 6 the number of common shares outstanding and the book value per common share on June 30, 2001, June 30, 2000 and June 30, 1999. No other change has been made to the Company's original Annual Report on Form 10-K, and the information contained therein has not been updated.

ACETO CORPORATION AND SUBSIDIARIES  
FORM 10-K/A  
FOR THE FISCAL YEAR ENDED JUNE 30, 2003

### TABLE OF CONTENTS

#### PART I.

- Item 1. Business
- Item 2. Properties
- Item 3. Legal Proceedings
- Item 4. Submission of Matters to a Vote of Security Holders

#### PART II.

- Item 5. Market for Registrant's Common Equity and Related Stockholder Matters
- Item 6. Selected Financial Data
- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
- Item 7A. Quantitative and Qualitative Disclosures About Market Risk
- Item 8. Financial Statements and Supplementary Data
- Item 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure
- Item 9A. Controls and Procedures

## Edgar Filing: ACETO CORP - Form 10-K/A

### PART III.

- Item 10. Directors and Executive Officers of the Registrant
- Item 11. Executive Compensation
- Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
- Item 13. Certain Relationships and Related Transactions
- Item 14. Principal Accountant Fees and Services

### PART IV.

- Item 15. Exhibits, Financial Statement Schedules, and Reports on Form 8-K

## PART I

### CAUTIONARY STATEMENT PURSUANT TO SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

THIS ANNUAL REPORT ON FORM 10-K AND THE INFORMATION INCORPORATED BY REFERENCE MAY INCLUDE "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT AND SECTION 21E OF THE EXCHANGE ACT. THE COMPANY INTENDS THE FORWARD-LOOKING STATEMENTS TO BE COVERED BY THE SAFE HARBOR PROVISIONS FOR FORWARD-LOOKING STATEMENTS. ALL STATEMENTS REGARDING THE COMPANY'S EXPECTED FINANCIAL POSITION AND OPERATING RESULTS, ITS BUSINESS STRATEGY, ITS FINANCING PLANS AND THE OUTCOME OF ANY CONTINGENCIES ARE FORWARD-LOOKING STATEMENTS. THE FORWARD-LOOKING STATEMENTS ARE BASED ON CURRENT ESTIMATES AND PROJECTIONS ABOUT OUR INDUSTRY AND OUR BUSINESS. WORDS SUCH AS "ANTICIPATES," "EXPECTS," "INTENDS," "PLANS," "BELIEVES," "SEEKS," "ESTIMATES," OR VARIATIONS OF SUCH WORDS AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY SUCH FORWARD-LOOKING STATEMENTS. THE FORWARD-LOOKING STATEMENTS ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE SET FORTH OR IMPLIED BY ANY FORWARD LOOKING STATEMENTS. FACTORS THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THE FORWARD-LOOKING STATEMENTS INCLUDE, BUT ARE NOT LIMITED TO: UNFORESEEN ENVIRONMENTAL LIABILITIES AND THE UNCERTAIN MILITARY, POLITICAL AND ECONOMIC CONDITIONS IN THE WORLD. THESE AND OTHER RISKS ARE DETAILED IN PART I, ITEM 1 "RISK FACTORS" AND ELSEWHERE IN THIS FORM 10-K. THE COMPANY ASSUMES NO OBLIGATION TO UPDATE PUBLICLY THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE, EXCEPT AS MAY BE REQUIRED BY LAW.

(Dollar and share amounts in thousands, except per share amounts)

### ITEM 1. BUSINESS

#### GENERAL

Aceto Corporation (together with its consolidated subsidiaries, the "Company" or "Registrant") was incorporated in 1947 in the State of New York. The Company is engaged in the marketing, sale and distribution of pharmaceutical, fine and industrial chemicals used principally in the agricultural, color producing, pharmaceutical, nutraceutical and surface coating industries. The Company sells approximately 1,000 chemicals used in these and other related industries.

#### REPORTABLE SEGMENTS

The Company, prior to fiscal 2002, was organized into six reportable segments, organized by product and as defined by accounting principles generally accepted in the United States of America. Effective for the fiscal year ended June 30, 2002, the two segments formerly known as Industrial Chemicals and Organic

## Edgar Filing: ACETO CORP - Form 10-K/A

Intermediates & Colorants were combined into a segment called Chemicals and Colorants. Effective for the fiscal year ended June 30, 2003, the two segments formerly known as Pharmaceuticals, Biochemicals & Nutritionals and Pharmaceutical Intermediates & Custom Manufacturing were combined into a segment called Health Sciences. The amounts previously reported for the former segments have been combined accordingly. Therefore, the Company's four reportable segments, organized by product are as follows:

(1) Agrochemicals, whose products include herbicides, fungicides and insecticides, as well as a sprout inhibitor for potatoes, (2) Chemicals and Colorants, whose products include a variety of specialty chemicals used in plastics, resins, adhesives, coatings, food, flava, fragrance,

1

cosmetics, metal finishing, electronics and many other areas in addition to dye and pigment intermediates used in the color-producing industries like textiles, inks, paper and coatings, as well as intermediates used in the production of agrochemicals; (3) Health Sciences, which include the active ingredients for generic pharmaceuticals, vitamins and nutritional supplements, as well as products used in preparation of pharmaceuticals, primarily by major innovative drug companies and (4) Institutional Sanitary Supplies & Other, whose products include cleaning solutions, fragrances and deodorants used by commercial and industrial establishments. The Company does not allocate assets by segment. The Company's chief decision maker evaluates performance of the segments based on gross profit.

Information concerning revenue and gross profit attributable to each of the Company's business segments is found in Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," and Part IV, Item 16, Note 16 of "Notes to Consolidated Financial Statements," of this Form 10-K, which information is incorporated by reference into this Part I, Item 1.

### PRODUCTS AND CUSTOMERS

During the fiscal years ended June 30, 2003 and 2002, approximately 59% and 60%, respectively, of the Company's purchases of chemicals came from Asia and approximately 29% and 25%, respectively, from Europe.

A majority of the Company's customers are located in the United States, though sales are made worldwide. The customers include a wide range of companies in the industrial chemical and pharmaceutical industries, and range from small trading companies to Fortune 500 corporations. During fiscal 2003 and 2002, 59% and 64% of sales, respectively, were in the United States. Sales made to customers outside the United States totaled \$110,298. Approximately 67% of these international sales were to customers in Germany, France, Australia, The Netherlands, the United Kingdom, Malaysia and Canada.

The chemical industry is highly competitive. The Company competes by offering high quality products produced around the world by both large and small manufacturers at attractive prices. The Company has the ability, based on its long relationship with many suppliers as well as its sourcing offices in China and India, to offer products manufactured at a facility that is appropriate for that product. For the most part, the Company stores its inventory of chemicals in public warehouses strategically located throughout the United States, Europe and Asia, and can therefore fill orders rapidly from inventory. The Company has developed ready access to key purchasing, research and technical executives of both its customers and suppliers and has the ability to obtain quick decisions, when necessary, because of such access. The Company does not consider itself to be a significant factor in the chemical and pharmaceutical industries taken as a

## Edgar Filing: ACETO CORP - Form 10-K/A

whole.

Total long-lived assets (excluding goodwill and intangible assets) in the United States were \$1,457 and \$1,731 as of June 30, 2003 and 2002, respectively. Total long-lived assets outside the United States were \$818 and \$701 at June 30, 2003 and 2002, respectively.

No single product accounted for as much as 10% of net sales in fiscal 2003, 2002 or 2001. No single customer accounted for as much as 10% of net sales in fiscal 2003, 2002 or 2001. One supplier accounted for 10% of purchases in fiscal 2003. No supplier accounted for as much as 10% of purchases in fiscal 2002 or 2001.

The Company holds no patents, trademarks, licenses, franchises or concessions which it considers to be material to its operations.

2

For the most part, the Company warehouses the products that it sells and fills orders from inventory.

A subsidiary of the Company, Aceto Agricultural Chemicals Corp., markets certain agricultural chemicals and contracts for the manufacture of other agricultural chemicals which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the Environmental Protection Agency (EPA) to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate the generation of new test data to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of three such task force groups. The Company may be required to make additional payments in the future.

Compliance with Federal, State and local regulations which have been enacted or adopted regarding the discharge of materials into the environment has not had a material effect on the capital expenditures and competitive position of the Company. During fiscal 1993, the Company announced the closing of its manufacturing subsidiary located in Carlstadt, New Jersey. At the same time an environmental consultant was engaged by the Company to determine the extent of contamination on the site and develop a plan of remediation. Based on the initial estimates from the consultant a liability of \$1,500 was recorded in fiscal 1993. During fiscal 1997, after additional testing was completed, the Company received a revised estimate from the consultant and an additional liability of \$800 was recorded. At June 30, 2002, the remaining liability was \$1,284.

During fiscal 2003, based on continued monitoring of the contamination on the site and the current proposed plan of remediation, the Company received a revised estimate from the consultant, which estimated that the remaining costs of the remediation could be an amount between \$1,550 and \$3,200. During fiscal 2003, the Company recorded an additional liability in the amount of \$266 resulting in a liability as of June 30, 2003 in the amount of \$1,550. However, these matters, if resolved in a manner different from those assumed in current estimates could have a material adverse effect on financial condition, operating results and cash flows when resolved in a future reporting period. Other than the remediation associated with the Carlstadt, New Jersey facility, the Company is not aware of any material environmental liabilities.

THE SCHWEIZERHALL PHARMA ACQUISITION

## Edgar Filing: ACETO CORP - Form 10-K/A

On March 26, 2001, the Company acquired (i) the distribution business of the Schweizerhall Pharma division of Schweizerhall Holding AG, a Switzerland corporation and (ii) certain assets relating to the Pharmaceutical Ingredients business of Schweizerhall, Inc., a New Jersey corporation, and a wholly owned subsidiary of Schweizerhall Holding AG (collectively, "Schweizerhall Pharma").

Schweizerhall Pharma's distribution business is an international pharmaceutical distribution business with offices located in: Hamburg, Germany; Wormerveer, The Netherlands (a suburb of Amsterdam); Paris, France; Piscataway, New Jersey; Singapore; Mumbai, India; and Hong Kong. Its principal activities are the supply of Active Pharmaceutical Ingredients and Advanced Intermediates.

3

The products sold by Schweizerhall Pharma are classified in the Company's Health Sciences segment; therefore there is no change in the types of products sold or the methods of distribution.

The total purchase price for the Schweizerhall Pharma acquisition was \$25,980. This amount consisted of 600 restricted shares of the Company's Common Stock, the assumption of \$8,966 of Schweizerhall Holding AG debt, \$5,973 in cash, the issuance of notes of \$4,626 and acquisition costs of \$1,240. The quoted market price of the Common Stock on March 26, 2001 of \$8.625 per share, was used to approximate the fair value of the 600 shares issued, which amounted to \$5,175. The shares may not be sold unless registered or unless an exemption from registration is available. In connection with the closing of the acquisition the Company assumed certain debt of Schweizerhall Holding AG in excess of the amount of the purchase price. As a result, at closing Schweizerhall Holding AG paid \$7,162 to the Company. Subsequent to March 31, 2001 the Company paid Schweizerhall Holding AG \$8,987 and was released from a portion of the debt assumed at closing.

At June 30, 2003, the Company employed approximately 240 persons, none of whom were covered by a collective bargaining agreement.

### RISK FACTORS

IF WE ARE UNABLE TO COMPETE EFFECTIVELY WITH OUR COMPETITORS, MANY OF WHOM HAVE A GREATER MARKET PRESENCE AND GREATER RESOURCES THAN US, OUR FINANCIAL CONDITION AND OPERATING RESULTS MAY BE ADVERSELY AFFECTED.

Our financial condition and operating results are directly related to our ability to compete in the intensely competitive worldwide chemical market. We face competition from global and regional distributors of chemical products, many of who are large chemical manufacturers as well as distributors. Many of these companies have substantially greater resources than us, including greater financial, marketing and distribution resources.

UNFORESEEN ENVIRONMENTAL LIABILITIES AND/OR COSTS ASSOCIATED WITH COMPLIANCE WITH ENVIRONMENTAL LAWS WOULD HAVE A NEGATIVE EFFECT ON OUR FINANCIAL PERFORMANCE.

If existing environmental regulations are changed, or additional laws or regulations are passed, the cost of complying with those laws may be substantial. No assurance can be given that we will not incur material environmental liabilities or that compliance with such laws will not require material capital expenditures by us, negatively affecting our financial performance. Our operations, the distribution of chemical products, are subject to various federal, state, local and foreign environmental laws and regulations. Many of these laws and regulations provide for substantial remediation costs in

## Edgar Filing: ACETO CORP - Form 10-K/A

the event of discharges of contaminants and fines and criminal sanctions for violations. We believe that we are currently in substantial compliance with all current environmental laws and regulations.

THE UNCERTAIN MILITARY, TERRORIST, POLITICAL AND ECONOMIC CONDITIONS IN THE WORLD COULD MATERIALLY DISRUPT OUR OPERATIONS CONDUCTED ABROAD AND EXPORT SALES.

Military, terrorist, political and economic actions in other countries could materially disrupt our overseas operations and export sales. In fiscal year 2003, approximately 41% of our revenues were attributable to operations conducted abroad and to export sales. In addition, in fiscal 2003, approximately 29% and 59% of the Company's purchases came from Europe and Asia, respectively. In addition, in certain countries where

4

we currently operate, export, intend to operate or intend to expand our operations, we could be subject to other political, military and economic uncertainties including labor unrest, restrictions on transfers of funds and unexpected changes in regulatory environments.

WE MAY FACE UNINSURED LIABILITIES INHERENT IN THE CHEMICAL INDUSTRY.

It is possible that liabilities for pollution and other damages arising from a major occurrence could exceed our insurance coverage or policy limits or that such insurance may not be available at reasonable rates in the future. Any such liabilities, which could arise due to injury and loss of life, severe damage to and destruction of property and equipment, pollution and other environmental damage could have a material adverse effect on us. The risks inherent in the chemical industry include explosions, fires, chemical spills or releases, pollution and other environmental risks. While we have considered and evaluated these risks, we believe that they currently do not have a significant impact on our operations.

BECAUSE OUR BUSINESS IS AFFECTED BY CHANGES IN CURRENCY MARKETS, FLUCTUATIONS IN FOREIGN CURRENCY EXCHANGE RATES MAY ADVERSELY AFFECT OUR RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

Our results of operations and financial condition may be adversely affected by fluctuations in the exchange rate between foreign currencies and the U.S. dollar. A substantial portion of our revenue is denominated in currencies other than the U.S. dollar because certain of our foreign subsidiaries operate in their local currencies. Moreover, we may incur significant costs in connection with conversions between currencies.

THE RECENT OUTBREAK OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) MAY ADVERSELY AFFECT OUR BUSINESS AND FINANCIAL CONDITION

Although the recent SARS epidemic has seemingly been contained, a new sudden outbreak of SARS, particularly in China, as well as concerns over its spread in Asia and elsewhere, could adversely affect our business and financial condition given the importance of our sales and production facilities in Asia. Specifically, if a new sudden SARS outbreak resulted in quarantines or closures of our suppliers' facilities in Asia, it would make it more difficult for us to conduct our business operations in Asia. On the other hand, we view the risk of any such quarantines or closures to be unlikely given that no such quarantines or closures occurred in the recent SARS epidemic, our suppliers are located in areas in China that are outside the metropolitan areas where SARS cases had been most prevalent, and the use of protective masks, headgears, disinfectants and cleaning solvents in the facilities substantially reduces the risk of such quarantines or closures.

## Edgar Filing: ACETO CORP - Form 10-K/A

### AVAILABLE INFORMATION

-----

We file annual, quarterly and current reports, proxy statements and other information with the United States Securities and Exchange Commission. You may read and copy any document we file at the SEC's public reference room at Room 1024, 450 Fifth Street, NW, Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for information on the public reference room. The SEC maintains a website that contains annual, quarterly and current reports, proxy statements and other information that issuers (including Aceto) file electronically with the SEC. The SEC's website is [WWW.SEC.GOV](http://WWW.SEC.GOV).

Our website is [WWW.ACETO.COM](http://WWW.ACETO.COM). We make available free of charge through our Internet site, via a link to the SEC's website at [WWW.SEC.GOV](http://WWW.SEC.GOV), our

5

annual reports on Form 10-K; quarterly reports on Form 10-Q; current reports on Form 8-K; Forms 3, 4 and 5 filed on behalf of our directors and executive officers; and any amendments to those reports filed or furnished pursuant to the Securities Exchange Act of 1934 as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information on our website is not incorporated by reference into this report.

#### ITEM 2. PROPERTIES

The Company's general headquarters and main sales office occupy approximately 26,000 square feet of leased space in an office building in Lake Success, New York. The lease expires in April 2011.

Two of the Company's subsidiaries, in the sanitary supply business, occupy 44,000 square feet of leased space in an industrial park in New Hyde Park, New York. The lease expires in November 2009.

The Company's former manufacturing facility is located on an 11-acre parcel in Carlstadt, New Jersey, owned by the Company. This parcel contains one building with approximately 5,000 square feet of office space. The property consisting of land and land improvements, is classified as held for sale on the Consolidated Balance Sheets.

The Company also has leases for office space in Waldshut, Germany; Hamburg, Germany; Wormerveer, The Netherlands; Paris, France; Lyon, France; Singapore; Shanghai, China and Mumbai, India. The offices are used for sales and administrative purposes.

The Company believes that its properties are generally well maintained, in good condition and adequate for its present needs.

#### ITEM 3. LEGAL PROCEEDINGS.

The Company is involved in a number of pending or threatened legal proceedings incidental to the business. We do not believe that any of the pending or threatened legal proceedings will have a material adverse effect on the financial position or operating results of the Company.

#### ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

No matters were submitted for a formal vote of the shareholders during the fourth quarter of the fiscal year covered by this Report.



# Edgar Filing: ACETO CORP - Form 10-K/A

## PART II

### ITEM 5. MARKET FOR THE COMPANY'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.

The Company's common stock is traded on the Nasdaq National Market using the symbol "ACET." The following table sets forth the 2003 and 2002 high and low sales prices of the Company's common stock as reported on the Nasdaq National Market for the periods indicated, adjusted for a 3-for-2 split of the common stock in the form of a 50% stock dividend paid in January 2003.

6

| FISCAL 2003    | HIGH    | LOW     |
|----------------|---------|---------|
| First Quarter  | \$ 7.82 | \$ 5.33 |
| Second Quarter | 11.99   | 5.61    |
| Third Quarter  | 14.63   | 8.96    |
| Fourth Quarter | 22.98   | 12.53   |

| FISCAL 2002    | HIGH    | LOW     |
|----------------|---------|---------|
| First Quarter  | \$ 6.58 | \$ 5.16 |
| Second Quarter | 6.89    | 5.91    |
| Third Quarter  | 7.75    | 6.17    |
| Fourth Quarter | 7.70    | 6.60    |

Cash dividends of \$0.115 per common share were paid in January 2003 and June 2003. Cash dividends of \$0.1067 per common share were paid in January and June 2002, adjusted for the 50% stock dividend paid in January 2003.

As of September 19, 2003, there were approximately 563 holders of record of the Company's common stock.

Shares held by the nominee of the Depository Trust Company, the country's principal central depository, were approximately 8,442 shares and counted as owned by one holder. Additional individual holdings in street name result in a sizable number of beneficial owners represented on our records as owned by various banks and stockbrokers.

The following table sets forth certain information with respect to our equity compensation plans at June 30, 2003 (shares in thousands):

| Plan Category  | Number of securities to be issued upon exercise of outstanding options | Weighted-average exercise price of outstanding options | Number of securities remaining available for future issuance under equity compensation plans |
|--|--|--|--|
| Equity compensation plans approved by security holders     | 963  | \$7.96   | 1,016  |
| Equity compensation plans not approved by security holders | -  | -  | -  |

Edgar Filing: ACETO CORP - Form 10-K/A

Total 963 \$7.96 1,016

7

ITEM 6. SELECTED FINANCIAL DATA

(In thousands, except per share amounts)

| Years Ended June 30  | 2003      | 2002      | 2001          | 2000      | 1999      |
|--|-----------|-----------|---------------|-----------|-----------|
| Net sales  | \$271,276 | \$229,329 | \$178,154 (1) | \$185,308 | \$169,000 |
| Income before cumulative effect of accounting change                         | 9,468     | 4,945     | 4,245         | 6,344     | 6,344     |
| Net income   | 7,595     | 4,945     | 4,245         | 6,344     | 6,344     |
| Income before cumulative effect of accounting change per share - diluted (2) | \$ 0.94   | \$ 0.50   | \$ 0.46       | \$ 0.67   | \$ 0.67   |
| Net income per common share - diluted (2)                                    | \$ 0.75   | \$ 0.50   | \$ 0.46       | \$ 0.67   | \$ 0.67   |
| Total assets   | 123,519   | 115,703   | 105,173       | 88,081    | 86,000    |
| Working capital  | 71,628    | 58,311    | 55,259        | 50,270    | 49,000    |
| Long-term liabilities  | -         | -         | 671           | 908       | -         |
| Redeemable preferred Stock   | -         | -         | -             | -         | -         |
| Shareholders' equity   | 84,569    | 73,290    | 69,203        | 63,604    | 63,000    |
| Number of common shares outstanding at year end (2)                          | 10,286    | 9,825     | 9,795         | 9,326     | 9,326     |
| Book value per common share (2)  | \$ 8.22   | \$ 7.46   | \$ 7.07       | \$ 6.82   | \$ 6.82   |
| Cash dividends per common share (2)  | \$ 0.23   | \$ 0.21   | \$ 0.21       | \$ 0.20   | \$ 0.20   |

## Edgar Filing: ACETO CORP - Form 10-K/A

- (1) Includes the acquisition of the Schweizerhall Pharma distribution business on March 26, 2001 as more fully described in Item 1.
- (2) Adjusted for stock splits as appropriate.

8

### ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

#### CAUTIONARY STATEMENT PURSUANT TO SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

THIS ANNUAL REPORT ON FORM 10-K AND THE INFORMATION INCORPORATED BY REFERENCE MAY INCLUDE "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT AND SECTION 21E OF THE EXCHANGE ACT. THE COMPANY INTENDS THE FORWARD-LOOKING STATEMENTS TO BE COVERED BY THE SAFE HARBOR PROVISIONS FOR FORWARD-LOOKING STATEMENTS. ALL STATEMENTS REGARDING THE COMPANY'S EXPECTED FINANCIAL POSITION AND OPERATING RESULTS, ITS BUSINESS STRATEGY, ITS FINANCING PLANS AND THE OUTCOME OF ANY CONTINGENCIES ARE FORWARD-LOOKING STATEMENTS. THE FORWARD-LOOKING STATEMENTS ARE BASED ON CURRENT ESTIMATES AND PROJECTIONS ABOUT OUR INDUSTRY AND OUR BUSINESS. WORDS SUCH AS "ANTICIPATES," "EXPECTS," "INTENDS," "PLANS," "BELIEVES," "SEEKS," "ESTIMATES," VARIATIONS OF SUCH WORDS AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY SUCH FORWARD-LOOKING STATEMENTS. THE FORWARD-LOOKING STATEMENTS ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE SET FORTH OR IMPLIED BY ANY FORWARD LOOKING STATEMENTS. FACTORS THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THE FORWARD-LOOKING STATEMENTS INCLUDE, BUT ARE NOT LIMITED TO: UNFORESEEN ENVIRONMENTAL LIABILITIES AND THE UNCERTAIN MILITARY, POLITICAL AND ECONOMIC CONDITIONS IN THE WORLD. THESE RISKS ARE DETAILED IN PART I, ITEM 1 "RISK FACTORS" AND ELSEWHERE IN THIS FORM 10-K. THE COMPANY ASSUMES NO OBLIGATION TO UPDATE PUBLICLY THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE, EXCEPT AS MAY BE REQUIRED BY LAW.

#### CRITICAL ACCOUNTING POLICIES

The Company's discussion and analysis of its financial condition and results of operations is based on its consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires the Company to make estimates and assumptions that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The Company evaluates its estimates on a regular basis, including those related to bad debts, inventories, goodwill and intangible assets, and environmental contingencies. The Company bases its estimates on various factors including historical experience, consultation and advice from third party subject matter experts and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and circumstances.

The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of its consolidated financial statements.

The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss to the customer. Such revenues do not involve difficult, subjective, or complex judgments. The Company does not offer product warranties to its customers.

## Edgar Filing: ACETO CORP - Form 10-K/A

The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. Allowances for doubtful accounts are based on historical experience and known factors regarding specific customers and industries in which the customers operate. If the financial condition of the Company's customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances would be required.

9

The Company writes down its inventories for estimated slow moving and obsolete goods equal to the difference between the carrying cost of the inventory and the estimated market value based upon assumptions about future demand and market conditions. A significant sudden increase in the demand for the Company's products could result in a short-term increase in the cost of inventory purchases while a significant decrease in demand could result in an increase in the amount of excess inventory quantities on-hand. Additionally, the Company's estimates of future product demand may prove to be inaccurate, in which case the Company may have understated or overstated the write-down required for excess and obsolete inventory. In the future, if the Company's inventory is determined to be overvalued, it would be required to recognize such costs in its cost of goods sold at the time of such determination. Likewise, if the Company does not properly estimate the lower of cost or market of its inventory and it is therefore determined to be undervalued, it may have over-reported its cost of goods sold in previous periods and would be required to recognize such additional operating income at the time of sale. Therefore, although the Company makes every effort to ensure the accuracy of its forecasts of future product demand, any significant unanticipated changes in demand could have a significant impact on the value of the Company's inventory and its reported operating results.

Goodwill is calculated as the excess of the cost of purchased businesses over the value of their underlying net assets. Other intangible assets principally consist of purchased customer lists and covenants not to compete. Goodwill and other intangible assets that have an indefinite life are not amortized.

The Company adopted Statement of Financial Accounting Standards (SFAS) No. 142, "Goodwill and Other Intangible Assets" (SFAS 142), effective July 1, 2002. As required by SFAS 142, the Company upon adoption performed impairment tests on goodwill as of July 1, 2002. As a result of the impairment tests, the Company recorded a goodwill impairment charge of \$1,873, which has been included as a cumulative effect of an accounting change in the accompanying consolidated statement of income for the year ended June 30, 2003. Also required by SFAS 142, on an annual basis, the Company tests goodwill and other intangible assets for impairment. To determine the fair value of these intangible assets, there are many assumptions and estimates used that directly impact the results of the testing. In making these assumptions and estimates, the Company uses industry accepted valuation models and set criteria that are reviewed and approved by various levels of management. Additionally, the Company utilizes the assistance of a third-party valuation firm, as necessary, to help evaluate recorded goodwill. If the estimates or their related assumptions used by the Company change in the future, the Company may be required to record impairment charges for these assets.

The Company establishes reserves for environmental matters and other contingencies when it is probable that a liability has been incurred and the amount of the liability is reasonably estimable. If the contingency is resolved for an amount greater or less than has been accrued, or the Company's share of the contingency increases or decreases, or other assumptions relevant to the development of the estimate were to change, the Company would recognize an

## Edgar Filing: ACETO CORP - Form 10-K/A

additional expense or benefit in income in the period such determination was made.

The Company has accounted for, and currently accounts for, income taxes in accordance with SFAS No. 109, "Accounting for Income Taxes." This Statement establishes financial accounting and reporting standards for the effects of income taxes that result from an enterprise's activities during the current and preceding years. It requires an asset and liability approach for financial accounting and reporting of income taxes.

As of June 30, 2003, the Company has current net deferred tax assets of \$301 and non-current net deferred tax assets of \$1,107. These net deferred tax assets have been recorded based on the Company having sufficient future earnings in order to realize these assets, and the net deferred tax assets have been provided for at currently enacted income tax rates. Included in net deferred tax assets is a valuation allowance of approximately \$5,537, which relates to foreign tax loss carryforwards not utilized to date. Management believes it is more likely than not

10

that the deferred tax assets will not be realized in the relevant jurisdiction. Based on the Company's assessments, no additional valuation allowance is required. If the Company determines that a deferred tax asset will not be realizable, an adjustment to the deferred tax asset will result in a reduction of earnings at that time.

Furthermore, the Company provides reserves for Federal, state and international tax exposures relating to audits, planning initiatives, and compliance responsibilities. The development of these reserves requires judgments about tax issues, potential outcomes and timing, and is a subjective critical estimate.

### RESULTS OF OPERATIONS:

| Segment                                    | Net Sales By Segment<br>Fiscal Year Ended June 30,<br>(Dollars in thousands) |               |                  |               |                  |
|--|--|---------------|------------------|---------------|------------------|
|  | 2003   |               | 2002             |               | 2001             |
|  | -----  |               | -----            |               | -----            |
|  | Sales  | % of<br>total | Sales            | % of<br>total | Sales            |
|  | -----  | -----         | -----            | -----         | -----            |
| Agrochemicals                              | \$ 14,356  | 5.3%          | \$ 13,540        | 5.9%          | \$ 13,133        |
| Chemicals and Colorants                    | 91,579   | 33.8          | 90,494           | 39.5          | 97,902           |
| Health Sciences                            | 159,858  | 58.9          | 120,021          | 52.3          | 61,137           |
| Institutional Sanitary<br>Supplies & Other | 5,483  | 2.0           | 5,274            | 2.3           | 5,982            |
|  | -----  | -----         | -----            | -----         | -----            |
| <b>TOTAL NET SALES</b>                     | <b>\$271,276</b>   | <b>100.0%</b> | <b>\$229,329</b> | <b>100.0%</b> | <b>\$178,154</b> |
|  | =====  | =====         | =====            | =====         | =====            |

Gross Profit By Segment  
Fiscal Year Ended June 30,  
(Dollars in thousands)

| Segment                                    | 2003<br>----             |                        | 2002<br>----             |                        | 2001<br>----             |
|--|--------------------------|------------------------|--------------------------|------------------------|--------------------------|
|  | Gross<br>Profit<br>----- | % of<br>total<br>----- | Gross<br>Profit<br>----- | % of<br>total<br>----- | Gross<br>Profit<br>----- |
| Agrochemicals                              | \$ 4,123                 | 8.5%                   | \$ 4,215                 | 10.5%                  | \$ 4,943                 |
| Chemicals and Colorants                    | 12,673                   | 26.0                   | 13,502                   | 33.5                   | 15,529                   |
| Health Sciences                            | 29,569                   | 60.6                   | 20,240                   | 50.3                   | 11,948                   |
| Institutional Sanitary<br>Supplies & Other | 2,418<br>-----           | 4.9<br>-----           | 2,294<br>-----           | 5.7<br>-----           | 1,562<br>-----           |
| TOTAL GROSS PROFIT<br>BY SEGMENT           | \$48,783                 | 100.0%                 | \$40,251                 | 100.0%                 | \$33,982                 |
| UNALLOCATED COST<br>OF SALES (1)           | 3,487<br>-----           |                        | 2,970<br>-----           |                        | 5,365<br>-----           |
| NET GROSS PROFIT                           | \$45,296<br>=====        |                        | \$37,281<br>=====        |                        | \$28,617<br>=====        |

(1) Represents freight and storage costs that are not allocated to a segment.

FISCAL YEAR ENDED JUNE 30, 2003 COMPARED TO FISCAL YEAR ENDED JUNE 30, 2002

SALES AND GROSS PROFIT

Net sales increased \$41,947 or 18.3%, to \$271,276 for the fiscal year ended June 30, 2003 compared with \$229,329 for the prior year. The Company reported particularly strong sales and gross profit for the year ended June 30, 2003 from its Health Sciences segment as explained below. Net sales for the other three segments combined were up \$2,110 or 1.9% in fiscal 2003.

The Health Sciences segment reported a significant increase in sales and accounted for 95.0% of the overall increase. This segment has achieved gains in market share and experienced strong demand for certain Active Pharmaceutical Ingredients of products launched during the fourth quarter of fiscal 2002 and the four quarters of fiscal 2003. This segment's sales were \$159,858 for the year ended June 30, 2003 versus \$120,021 last year, an increase of \$39,837 or

## Edgar Filing: ACETO CORP - Form 10-K/A

33.2%. A majority of the increase resulted from the initial and follow up shipments of several generic pharmaceutical products which are sold to companies who have received recent approval to market these products. In addition, the increase was attributable to increased sales volume from an expanded distribution agreement with a major supplier which allows for the sale of additional products into new markets. The nutritional business showed a 10.6% increase in volume this year due to increased demand for products such as nutritional supplements.

The Chemicals & Colorants segment achieved an increase of \$1,085 or 1.2%, to \$91,579 in 2003 compared to \$90,494 last year. The increase is attributable to an increase in volume with one large customer and some improved pricing in color intermediates which was somewhat offset by lost sales from two former customers and continuing declines in sales volume related to the pigment and dyestuff industries.

Agrochemicals sales were \$14,356 for 2003 compared to \$13,540 last year, an increase of \$816 or 6.0%. A restructuring of the Company's arrangement with a third party, effective October 1, 2001, resulted in additional sales of \$739 during the quarter

12

ended September 30, 2002. Excluding this, sales increased by \$77 or 0.5%. Sales were flat due to a one-time sale of offgrade material to one customer recorded in 2002 offset by an overall increase in volume in fiscal 2003 for the segment's main products.

Institutional Sanitary Supplies & Other sales were \$5,483 for 2003 compared to \$5,274 last year, an increase of \$209 or 4.0%. The improved sales were attributable to price increases and identifying better sources of supply that have improved our competitive position regarding pricing. During 2002, this segment was also specifically disrupted by the after effects on the economy from the terrorist attacks of September 11, 2001. Over 30% of this segment's customer base is in the New York metropolitan area.

Gross profit by segment before unallocated cost of sales (primarily storage and certain freight costs) increased 21.2%, to \$48,783 from \$40,251. The Health Sciences segment made the largest contribution to the overall improvement as it accounted for \$9,329 or 109.3% of the overall increase.

The gross profit resulting from the Health Sciences segment amounted to \$29,569, or 18.5% in fiscal 2003 versus \$20,240 or 16.9% in the prior year. Gross profit improvement was mainly attributable to the sales of several generic pharmaceutical products as described above in the sales comments. These products provided substantial increases in gross profit dollars at a slightly higher gross margin rate. Gross profit improvement was also attributable to the increased volume from an expanded distribution agreement with a major supplier for new products in both existing and new markets. In addition, nutritional also achieved a gross profit increase this year in dollars as a result of increased demand at similar margin rates.

The Chemicals & Colorants segment's gross profit of \$12,673 decreased \$829 or 6.1% over last year's \$13,502. Gross profit, as a percentage of sales, declined to 13.8% this year versus 14.9%. The current year's gross profit includes the net benefit of a negotiated settlement for lost gross profit regarding non-performance of a sales contract and an estimate of a loss on the related purchase contract in the amount of \$450. The decrease in gross profit excluding this favorable settlement would have been \$1,279 or 9.5%. The gross profit rate for this year would have been 13.5% excluding the settlement which is lower than the gross profit rate in the prior year of 14.9%. The decrease in gross profit

## Edgar Filing: ACETO CORP - Form 10-K/A

rate is primarily a result of increased sales volume from one large customer at lower than usual gross profit rates which has been combined with continued erosion of margins and gross profit dollars in various business sectors due to competitive pressures and economic sluggishness. The loss of several large customers in early fiscal 2003 also contributed to the decrease in gross profit dollars.

The Agrochemicals segment showed a decrease in gross profit of \$92 or 2.2% from \$4,123 in fiscal 2003 versus \$4,215 last year. The decrease in gross profit dollars resulted from increased packaging costs and overall product mix offset by an increase in sales volume. Gross margin was 28.7% in fiscal 2003 versus 31.1% last year.

Institutional Sanitary Supplies and Other gross profits were \$2,418 or 44.1% in 2003 versus \$2,294 or 43.5% in 2002. The 5.4% increase in gross profit dollars is mainly a result of a 4.0% increase in sales. Overall product mix and price increases were the main reasons for the higher margins this year.

Unallocated cost of sales increased to \$3,487 from \$2,970 or 17.4%. The higher costs were mainly a result of higher freight costs due to rising fuel surcharges, increased sales and shipments to customers and higher amounts of inventory in warehouses.

### SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Selling, general and administrative expenses ("SG&A") increased \$2,414 or 8.1% to \$32,359 for fiscal 2003 from \$29,945 for fiscal 2002. As a percentage of sales,

13

SG&A decreased to 11.9% for fiscal 2003 versus 13.1% for fiscal 2002. SG&A increased primarily due to rising business insurance costs, increased selling expenses and overall increases in employee wages, incentive compensation and fringe benefit costs. The Company sold property held for sale in July 2002 and realized a net gain on the sale of \$291. This gain reduced the overall SG&A expenses and lowered its SG&A as a percentage of sales. SG&A, as a percentage of sales, excluding this transaction would have been 12.0% versus 13.1% last year. SG&A grew 8.1% which was a slower rate than the sales increase of 18.3% which resulted in the decrease in SG&A as a percentage of sales.

### OPERATING PROFIT

For the year ended June 30, 2003 the operating income was \$12,937 compared to \$7,336, an increase of \$5,601 or 76.3%. This increase was primarily due to the overall increase in gross profit of \$8,015, with the main contribution of \$9,329 coming from the Health Sciences segment, which was partially offset by higher SG&A expenses of \$2,414.

### INTEREST AND OTHER INCOME

Interest expense for fiscal 2003 was \$284 versus \$368 in the prior year. The decrease of \$84 or 22.8% was attributable to the lower levels of short-term bank loans and acquisition-related debt from the Schweizerhall Pharma acquisition and lower average interest rates. Short-term bank loans was \$7,336 at June 30, 2002 versus \$3,286 at June 30, 2003. There was no acquisition-related debt remaining as of June 30, 2002 and 2003.

Interest and other income increased to \$713 for fiscal 2003 compared to \$410 last year. Interest income increased \$246 this year due to higher average balances in interest bearing accounts and increased finance charges received from a major customer. Miscellaneous sources of other income realized an increase of \$151 in 2003 versus the prior year. This was offset by a reduction in dividend income of \$57 and a loss on marketable securities of \$74 this year



## Edgar Filing: ACETO CORP - Form 10-K/A

compared to a loss of \$37 in the prior year.

### TAX RATES

The effective tax rate for the year ended June 30, 2003 decreased to 29.2% from 33.0% last year. The decrease in the effective tax rate is primarily a reflection of increased earnings in lower foreign tax jurisdictions compared to the prior year.

### CUMULATIVE EFFECT OF A CHANGE IN ACCOUNTING PRINCIPLE

The year ended June 30, 2003 includes a one-time charge of \$1,873, or \$0.19 per diluted share, attributable to the cumulative effect of adopting SFAS No. 142, "Goodwill and Other Intangible Assets". The Company's \$1,873 one-time charge was related to the impairment of the goodwill associated with CDC Products Corp. ("CDC") which is part of our Institutional Sanitary Supply segment. The one-time charge for CDC was primarily due to recent operating profits and cash flows being lower than expected due to increased competition from local sanitary supply companies in the markets CDC operates.

### FISCAL YEAR ENDED JUNE 30, 2002 COMPARED TO FISCAL YEAR ENDED JUNE 30, 2001

#### SALES AND GROSS PROFIT

Net sales increased \$51,175 or 28.7%, to \$229,329 for the fiscal year ended June 30, 2002 compared with \$178,154 for the prior year. Fiscal 2002 sales attributable to the acquisition of Schweizerhall Pharma, which closed on March 26, 2001, were \$60,701 compared to \$17,798, which were all recorded in the fourth quarter of fiscal 2001. The increase in these sales of \$42,903 accounts for 83.8% of the Company's overall increase. The only segment which had sales contributions from the Schweizerhall Pharma business is the Health Sciences segment. Sales excluding the Schweizerhall Pharma business were \$168,628 for 2002 versus \$160,356 for 2001, an increase of \$8,272 or 5.2%.

The Health Sciences segment sales were \$120,021 in fiscal 2002 and \$61,137 in 2001, an increase of \$58,884 or 96.3%. This segment now represents the largest segment of the Company in both net sales and gross profit. The acquisition in March 2001

14

contributed sales of \$60,701 and \$17,798 in fiscal 2002 and 2001, respectively. The segment's sales, excluding the Schweizerhall Pharma portion, were \$59,320 in 2002 versus \$43,339 in 2001, an increase of \$15,981 or 36.9%. This increase was a direct result of increased volume in one generic pharmaceutical product and the initial shipments of several generic pharmaceutical products which have been in development for the past several years. In addition, the increase is attributable to increased sales volume from the introduction of new products, especially in the fourth quarter, which was somewhat offset by lost sales from customers who purchased chemicals provided by this segment's former primary supplier. That supplier terminated a supply agreement in October 2000. The nutritionals business showed a slight decline in 2002 versus 2001 due to softer demand for nutritional supplements.

The Chemicals & Colorants segment saw an overall decrease of \$7,408 or 7.6%, to \$90,494 in 2002 from \$97,902 in 2001. This decrease reflects a general slowdown in the economy and in the entire industrial chemicals market. Also, the shrinking dye stuff industry in the United States caused sales to decline. In addition, the pigment industry has had economic difficulties, with the advertising sector in particular, resulting in decreased demand.

Agrochemicals sales were \$13,540 compared to \$13,133, an increase of \$407 or 3.1%. A restructuring of the Company's arrangement with a third party resulted in additional sales of \$3,171 during the year ended June 30, 2002. Excluding

## Edgar Filing: ACETO CORP - Form 10-K/A

this, sales decreased by \$2,764 or 21.0%. The primary causes were a reduction of sales to one large customer as well as an overall decline in demand.

Institutional Sanitary Supplies & Other sales were \$5,274 for 2002 versus \$5,982 last year, a decrease of \$708 or 11.8%. The decline was attributable to an overall decline in demand due to the general economic slowdown in the United States during this past year. This segment was also specifically disrupted by the after effects on the economy from the terrorist attacks of September 11, 2001. Over 30% of this segment's customer base is in the New York metropolitan area.

Gross profit by segment before unallocated cost of sales (primarily storage and certain freight costs) increased 18.4%, to \$40,251 from \$33,982. The inclusion of Schweizerhall Pharma, again in the Health Sciences segment, accounted for \$8,974 in 2002 and \$2,808 in 2001. Gross profit on our continuing domestic and certain foreign sales increased 0.3%, to \$31,277 from \$31,174 in 2001.

The gross margins in 2002 resulting from the Schweizerhall Pharma business in the Health Sciences segment amounted to \$8,974, or 14.8% versus \$11,266 or 19.0% for the rest of this segment's business. For fiscal 2001, the comparable gross margins were \$4,226 or 23.7% for the Schweizerhall Pharma business versus \$7,722 or 17.8% for all other business in the segment. The gross margins realized from the Schweizerhall Pharma business in this segment are generally lower than the margins earned by our traditional business due to a different pricing and product mix.

The Agrochemicals segment showed a decline in gross profit of 14.7%, which was in contrast to the 3.1% increase in sales. The restructuring of the Company's arrangement referred to earlier led to an increase in sales, but the same gross profit contribution. This is the primary cause of this discrepancy between sales and gross profit percentages for the period.

The Chemicals & Colorants segment's gross profit declined 13.1%, which was significantly higher than the 7.6% decline in sales. Continued erosion of margins due to competitive pressures in many areas, particularly printing inks and electronic chemicals, caused this higher percentage decrease in margins than sales.

Institutional Sanitary Supplies and Other gross margins were 43.5% in 2002 versus 26.1% in 2001. The increased gross margins are a direct result of changes from a pricing review, lower costs and product mix.

Unallocated cost of sales declined significantly to \$2,970 from \$5,365, or 44.6%. The results were achieved by lower amounts of inventory in warehouses, lower

15

quantity sold and a negotiated reduction of storage rates paid as part of a corporate initiative.

### SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Selling, general and administrative expenses ("SG&A") increased \$7,184 or 31.6% to \$29,945 for fiscal 2002 from \$22,761 for fiscal 2001. As a percentage of sales, SG&A increased to 13.1% for fiscal 2002 versus 12.8% for fiscal 2001. SG&A increased primarily due to the acquisition of the distribution business of Schweizerhall Pharma in March 2001. SG&A costs for this business increased \$6,243 to \$8,163 in fiscal 2002 versus \$1,920, which were all recorded in the fourth quarter of fiscal 2001. Other factors contributing to the increase were: rising employee health insurance costs, additional professional fees related to the Company's tax strategy and global restructuring projects, higher office

## Edgar Filing: ACETO CORP - Form 10-K/A

rental costs due to additional space taken, a higher bad debt provision and increased business insurance premiums.

### OPERATING PROFIT

For the year ended June 30, 2002 the operating profit was \$7,336 compared to \$5,856, an increase of \$1,480 or 25.3%. This increase was primarily due to a full year's positive contribution to operating profits from the Schweizerhall Pharma business, acquired on March 26, 2001, which was offset by higher SG&A expenses.

### INTEREST AND OTHER INCOME

Interest and other income decreased to \$410 for 2002 from \$1,226 last year. The reduction in income of \$816 was mainly attributable to a reduction in interest on investments of \$311 due to the holding of long-term investments during last year of over \$6,000 which were subsequently sold in the second half of fiscal 2001 to help finance the acquisition of Schweizerhall Pharma in March 2001.

Interest expense for 2002 was \$368 versus \$296 in the prior year. The increase of \$72 or 24.3% was entirely attributable to the short-term bank loans and acquisition related debt arising from the Schweizerhall Pharma acquisition. The total balance of this debt was reduced from \$11,177 at June 30, 2001 to \$7,336 at June 30, 2002 through debt payments totaling \$3,841.

### TAX RATES

The effective tax rates were 33.0% and 37.4% in fiscal 2002 and 2001, respectively. The decrease in the effective tax rate is primarily a reflection of earnings in lower tax jurisdictions due to the Schweizerhall Pharma acquisition.

### LIQUIDITY AND CAPITAL RESOURCES:

At June 30, 2003, the Company had \$20,263 in cash, \$877 in short-term investments and \$3,286 of short-term bank loans. Working capital was \$71,628 at June 30, 2003 versus \$58,311 at June 30, 2002.

The Company's cash position at June 30, 2003 increased \$6,008 from the June 30, 2002 level. Operating activities provided cash of \$9,132, primarily from net income of \$7,595, a reduction in other receivables of \$2,937 and increases in accrued compensation and accounts payable totaling \$4,364, partially offset by increases in inventory of \$5,425 due primarily to an increase in sales volume and trade accounts receivable of \$1,870, as well as a decrease in drafts and acceptances payable of \$2,758 and a decrease in accrued income taxes of \$1,582.

Investing activities provided cash of \$48, primarily from \$173 of net cash proceeds from the sale of property and proceeds from an investment held to maturity of \$369 which was partially offset by capital expenditures of \$590. Financing activities used cash of \$3,172 primarily as a result of payments of cash dividends of \$2,316 and payments of current installments of long-term liabilities of \$272 and short-term bank loans of \$4,050, which were partially offset by proceeds from the exercise of stock options of \$3,269.

In connection with the acquisition of Schweizerhall Pharma in March 2001, the acquired companies had existing credit facilities with two European financial institutions. These facilities provide the Company with a line of credit of 14,500 Euros (\$16,588) of which \$3,286 was utilized as of June 30, 2003. The Company is not subject to any financial covenants under these arrangements. Additionally, in May 2002, the Company entered into a \$15,000 revolving credit agreement with a financial institution, which expires June 30, 2004. At June 30, 2003, the Company utilized \$1,199 in letters of credit leaving an unused facility of \$13,801. Under the credit agreement, the Company may obtain credit

## Edgar Filing: ACETO CORP - Form 10-K/A

through direct borrowings and letters of credit. The obligations of the Company under the credit agreement are guaranteed by certain of the Company's subsidiaries and is secured by sixty-five percent of the capital of certain non-domestic subsidiaries which the Company owns. There is no borrowing base on the credit agreement. Interest under the credit agreement is at LIBOR plus 1.50%. The credit agreement contains several financial covenants requiring, among other things, minimum levels of debt service and tangible net worth. The Company is also subject to certain restrictive debt covenants including liens, limitations on indebtedness, guarantees, sale of assets, sales of receivables, and loans and investments. In March 2003, the Company obtained a waiver to its credit agreement which allowed it to guarantee an obligation of one of its wholly-owned subsidiaries to a vendor under a distribution agreement. The Company was in compliance with all covenants at June 30, 2003.

The Company has no material financial commitments other than those under operating lease agreements, letters of credit and unconditional purchase obligations. The Company continually evaluates possible acquisitions of or investments in businesses that are complementary to those of the Company, which transactions may require the use of cash. The Company believes that its cash, other liquid assets, operating cash flows, borrowing capacity and access to the equity capital markets, taken together, provide adequate resources to fund ongoing operating expenditures and the anticipated continuation of semi-annual cash dividends. Further, the Company may obtain additional credit facilities to enhance its liquidity.

The Company has certain contractual cash obligations and other commercial commitments which will impact its short and long-term liquidity. At June 30, 2003, the Company has no significant obligations for capital expenditures. At June 30, 2003, contractual cash obligations and other commercial commitments are as follows:

|                                       | Payments Due and/or<br>Amount of Commitment<br>Expiration Per Period |                     |                 |                |                  |
|---------------------------------------|--|---------------------|-----------------|----------------|------------------|
|                                       | Total  | Less Than<br>1 Year | 1-3<br>Years    | 4-5<br>Years   | After<br>5 Years |
| Long-term liabilities/<br>bank loans  | \$ 3,286   | \$ 3,286            | \$ -            | \$ -           | \$ -             |
| Operating leases                      | 9,373  | 1,418               | 2,665           | 2,349          | 2,941            |
| Commercial letters of credit          | 1,199  | 1,199               | -               | -              | -                |
| Standby letters of credit             | 122  | 122                 | -               | -              | -                |
| Unconditional purchase<br>obligations | 23,193   | 22,358              | 835             | -              | -                |
| <b>Total</b>                          | <b>\$37,173</b>  | <b>\$28,383</b>     | <b>\$ 3,500</b> | <b>\$2,349</b> | <b>\$2,941</b>   |

## Edgar Filing: ACETO CORP - Form 10-K/A

### IMPACT OF NEW ACCOUNTING PRONOUNCEMENTS

In July 2002, the FASB issued No. 146, "Accounting for Costs Associated with Exit or Disposal Activities". SFAS 146 will spread out the reporting of expenses related to restructurings initiated after 2002, because commitment to a plan to exit an activity or dispose of long-lived assets will no longer be enough to record a liability for the anticipated costs. Instead, companies will record exit and disposal costs when they are "incurred" and can be measured at fair value, and they will subsequently adjust the recorded liability for changes in estimated cash flows. The Company adopted the provisions of SFAS 146 as of January 1, 2003. The adoption of this statement did not have a significant impact on the Company's consolidated financial statements.

In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure" (SFAS 148). SFAS 148 provides alternative methods of transition for a voluntary change to the fair value method of accounting for stock-based employee compensation as originally defined by SFAS No. 123, "Accounting for Stock-Based Compensation." Additionally, SFAS 148 amends the disclosure requirements of SFAS No. 123 to require prominent disclosure in both the annual and interim financial statements about the method of accounting for stock-based compensation and the effect of the method used on reported results. The transitional requirements of SFAS 148 are effective for all financial statements for fiscal years ending after December 15, 2002. The Company adopted the disclosure portion of this statement for the fiscal quarter ended March 31, 2003. The application of the disclosure portion of this standard had no impact on the Company's consolidated financial position or results of operations. The FASB recently indicated that it will require stock-based employee compensation to be recorded as a charge to earnings pursuant to a standard on which it is currently deliberating. The FASB anticipates issuing an Exposure Draft in the fourth quarter of 2003 and a final statement in the second quarter of 2004. The Company will continue to monitor the FASB's progress on the issuance of this standard as well as evaluate the Company's position with respect to current guidance.

In April 2003, the FASB issued SFAS No. 149, "Amendment of Statement 133 on Derivative Instruments and Hedging Activities", which amends and clarifies accounting for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities under SFAS No. 133. SFAS No. 149 is effective for contracts entered into or modified after June 30, 2003 and for hedging relationships designated after June 30, 2003. The Company does not believe that the adoption of SFAS No. 149 will have a material impact on its consolidated financial statements.

In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain Financial Instruments with Characteristics of both Liability and Equity", which establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liability and equity in its statement of financial position. SFAS No. 150 is effective for new or modified financial instruments beginning July 1, 2003 and for existing instruments beginning August 1, 2003. The Company does not believe that the adoption of SFAS No. 150 will have a material impact on its consolidated financial statements.

In November 2002, the FASB issued Interpretation No. 45, "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness to Others" ("Int. No. 45"), which addresses the disclosure to be made by a guarantor in its interim and annual financial statements about its obligations under guarantees. Int. No. 45 also requires the guarantor to recognize a liability for the non-contingent component of the guarantee, which is the obligation to stand ready to perform in the event that specified triggering events or conditions occur. The recognition and measurement provisions of Int. No. 45 are effective for all guarantees entered into or modified after December 31, 2002. The Company has not entered into any such

## Edgar Filing: ACETO CORP - Form 10-K/A

guarantees and therefore the adoption of this standard did not impact the Company's consolidated financial statements.

In January 2003, the FASB issued Interpretation No. 46, "Consolidation of Variable Interest Entities," ("Int. No. 46") an interpretation of ARB No. 51. Int. No. 46 addresses consolidation by business enterprises of variable interest entities. Int.

18

No. 46 applies immediately to variable interest entities created after January 31, 2003 and to variable interest entities in which an enterprise obtains an interest after that date. Int. No. 46 applies in the first year or interim period beginning after June 15, 2003 to variable interest entities in which an enterprise holds a variable interest that it acquired before February 1, 2003. The Company is in the process of determining the impact of implementing Int. No. 46 on its consolidated financial statements.

### ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

#### Market Risk Sensitive Instruments

The market risk inherent in the Company's market risk sensitive instruments and positions is the potential loss arising from adverse changes in market price, foreign currency exchange rates and interest rates.

#### Market Price Risk

Short-term investments at June 30, 2003 of \$877 which consists solely of corporate securities and are recorded at fair value have exposure to price risk. This risk is estimated as the potential loss in fair value resulting from a hypothetical 10% adverse change in prices quoted by stock exchanges and amounts to \$88 as of June 30, 2003. Actual results may differ.

#### Foreign Currency Exchange Risk

In order to reduce the risk of foreign currency exchange rate fluctuations, the Company hedges some of its transactions denominated in a currency other than the functional currencies applicable to each of its various entities. The instruments used for hedging are short term foreign currency contracts (futures). The changes in market value of such contracts have a high correlation to price changes in the currency of the related hedged transactions. At June 30, 2003, the Company had foreign currency contracts outstanding that have a notional amount of \$3,431. The difference between the fair market value of the foreign currency contracts and the related commitments at inception and the fair market value of the contracts and the related commitments at June 30, 2003 was \$99.

In addition, the Company also enters into cross currency interest rate swaps to reduce foreign currency exposure on intercompany transactions. In May 2003, the Company entered into a five-year cross currency interest rate swap transaction for the purpose of hedging fixed interest rate, foreign currency denominated cash flows under an inter-company loan receivable. Under the terms of this derivative financial instrument, U.S. dollar-fixed principal and interest payments to be received under an intercompany loan will be swapped for EURO denominated fixed principal and interest payments. The fair market value of the swap at June 30, 2003 was \$(131). The gains or losses on the foreign currency loan receivable will be offset by the gains or losses on the swap. Because the Company is receiving fixed interest payments under the swap, it is still subject to fluctuations in value due to changes in Euro and U.S. dollar foreign currency

## Edgar Filing: ACETO CORP - Form 10-K/A

rates and U.S. dollar interest rates. As of June 30, 2003 the impact of these fluctuations was not significant. This hedge was deemed to be highly effective as of June 30, 2003.

The Company is subject to risk from changes in foreign exchange rates for its subsidiaries that use a foreign currency as their functional currency and are translated into U.S. dollars. These changes result in cumulative translation adjustments which are included in accumulated other comprehensive income (loss). On June 30, 2003, the Company had translation exposure to various foreign currencies with the most significant being the Euro and Singapore Dollars. The potential loss resulting from a hypothetical 10% adverse change in quoted foreign currency exchange rates, as of June 30, 2003, amounts to \$2,046. Actual results may differ.

### Interest Rate Risk

The Company is subject to market risk from exposure to changes in interest rates based upon its financing, investing and cash management activities. The Company utilizes a balanced mix of debt maturities along with both fixed-rate and variable-rate debt to manage its exposure to changes in interest rates. The Company's financial instrument holdings at year-end were analyzed to determine their sensitivity to interest rate changes. In this sensitivity analysis, the Company used the same change in interest rate for all maturities. All other factors were held constant. If there were an adverse change in interest rates of 10%, the expected effect on net income related to our financial instruments would be immaterial. However, there can be no assurances that interest rates will not significantly affect its results of operations.

19

### ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

The financial statements required by this item 8 are set forth at the end of this report. The following is the applicable supplementary data:

The following is a summary of the unaudited quarterly results of operations for the years ended June 30, 2003 and 2002.

#### QUARTERLY FINANCIAL DATA (Unaudited) (In thousands except per share amounts)

|  | Year Ended June 30, 2003 |               |               |               |
|--|--------------------------|---------------|---------------|---------------|
|  | Quarter Ended            |               |               |               |
|  | Sept. 30, 2002           | Dec. 31, 2002 | Mar. 31, 2003 | June 30, 2003 |
|  | -----                    | -----         | -----         | -----         |
| Net sales  | \$68,022                 | \$64,633      | \$70,561      | \$68,060      |
| Gross profit   | 11,245                   | 11,006        | 11,794        | 11,251        |
| Income before<br>cumulative<br>effect of<br>accounting<br>change                     | 2,323                    | 2,328         | 2,411         | 2,406         |
| Net income   | 450 (2)                  | 2,328         | 2,411         | 2,406         |
| Income before<br>cumulative<br>effect of<br>accounting<br>change per<br>common share |                          |               |               |               |

## Edgar Filing: ACETO CORP - Form 10-K/A

|                             |          |      |      |      |
|-----------------------------|----------|------|------|------|
| - diluted (1)               | 0.24     | 0.23 | 0.24 | 0.23 |
| Net income per common share |          |      |      |      |
| - diluted (1) (2)           | 0.05 (2) | 0.23 | 0.24 | 0.23 |

### Year Ended June 30, 2002 Quarter Ended

|                             | Sept. 30, 2001 | Dec. 31, 2001 | Mar. 31, 2002 | June 30, 2002 |
|-----------------------------|----------------|---------------|---------------|---------------|
|                             | -----          | -----         | -----         | -----         |
| Net sales                   | \$47,641       | \$55,365      | \$61,594      | \$64,729      |
| Gross profit                | 7,246          | 9,466         | 9,757         | 10,812        |
| Net income                  | 535            | 1,243         | 1,523         | 1,644         |
| Net income per common share |                |               |               |               |
| - diluted (1)               | 0.05           | 0.13          | 0.15          | 0.17          |

(1) Adjusted for a 3-for-2 stock split of the common stock, paid January 2, 2003.

(2) Reflects a charge of \$1,873 for a cumulative effect of an accounting change resulting from an impairment of goodwill which was determined to be required upon the Company's adoption of SFAS 142.

Net income per common share calculation for each of the quarters is based on weighted average number of shares outstanding in each period. Therefore, the sum of the quarters in a year does not necessarily equal the year's net income per common share.

#### ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

20

#### ITEM 9A. CONTROLS AND PROCEDURES

As required by Securities and Exchange Commission rules, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Annual Report. This evaluation was carried out under the supervision and with the participation of our management, including our principal executive officer and principal financial officer. Based on this evaluation, these officers have concluded that the design and operation of our disclosure controls and procedures are effective. There were no significant changes to our internal controls or in other factors that could significantly affect internal controls subsequent to the date of their evaluation.

Disclosure controls and procedures are our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file under the Exchange Act is accumulated and communicated to our management, including principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.



## Edgar Filing: ACETO CORP - Form 10-K/A

The Company is working closely with its corporate and securities lawyers to ensure that it maintains compliance with the Sarbanes-Oxley Act of 2002, the SEC regulations promulgated pursuant to that Act, and any related NASDAQ Stock Market rules.

### PART III

#### ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE COMPANY

Incorporated herein by reference to the Company's Definitive Proxy Statement with respect to the Company's Annual Meeting of Shareholders scheduled to be held on December 4, 2003.

#### ITEM 11. EXECUTIVE COMPENSATION

Incorporated herein by reference to the Company's Definitive Proxy Statement with respect to the Company's Annual Meeting of Shareholders scheduled to be held on December 4, 2003.

#### ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Incorporated herein by reference to the Company's Definitive Proxy Statement with respect to the Company's Annual Meeting of Shareholders scheduled to be held on December 4, 2003.

#### ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Incorporated herein by reference to the Company's Definitive Proxy Statement with respect to the Company's Annual Meeting of Shareholders scheduled to be held on December 4, 2003.

21

#### ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

Incorporated herein by reference to the Company's Definitive Proxy Statement with respect to the Company's Annual Meeting of Shareholders scheduled to be held on December 4, 2003.

### PART IV

#### ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K.

- (a) The Financial Statements listed in the Index to Consolidated Financial Statements are filed as part of this report.
- (b) Reports on Form 8-K.  
The Company filed a Form 8-K on May 8, 2003 furnishing its earnings release in connection with its third quarter.
- (c) Exhibits
  - 3.1 Restated Certificate of Incorporation (incorporated by reference to Exhibit 4(a)(iii) to Registration Statement No. 2-70623 on Form S-8 (S-8 2-70623)).
  - 3.2 Certificate of Amendment dated November 21, 1985 to Restated Certificate of Incorporation (incorporated by reference to Exhibit 3(ii) to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1986).

## Edgar Filing: ACETO CORP - Form 10-K/A

- 3.3 By-laws (incorporated by reference to Exhibit 3(iii)(c) to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1998).
- 10.1 Profit Sharing Plan, as amended and restated effective July 1, 1989 (incorporated by reference to Exhibit 10(iii)(a) to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1995).
- 10.2 401(k) Plan, effective August 1, 1997, (incorporated by reference to Exhibit 10 (iii) to the Company's Annual Report on Form 10-K for the year ended June 30, 1998).
- 10.3 Supplemental Executive Retirement Plan, effective June 30, 1985, as amended and restated, effective July 1, 1992 (incorporated by reference to Exhibit 10(iv)(a) to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1993).
- 10.4 Aceto Corporation Stock Option Plan (as Amended and Restated effective as of September 19, 1990) (and as further Amended effective June 9, 1992) (incorporated by reference to Exhibit 10(v)(b) to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1992).
- 10.5 1998 Aceto Corporation Omnibus Equity Award Plan (incorporated by

22

reference to Exhibit 10(v) to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1999).

- 10.6 Lease between Aceto Corporation and M. Parisi & Son Construction Co., Inc. for office space at One Hollow Lane, Lake Success, NY dated April 28, 2000 (incorporated by reference to Exhibit 10(vi) to the Company's Annual Report Form 10-K for the fiscal year ended June 30, 2000).
- 10.7 Lease between Aceto Corporation and M. Parisi & Son Construction Co., Inc. for office space at One Hollow Lane, Lake Success, NY dated April 28, 2000 (incorporated by reference to Exhibit 10(vi)(b) to the Company's Annual Report on Form 10-K for the year ended June 30, 2000).
- 10.8 Lease between CDC Products Corp. and Seaboard Estates for manufacturing and office space at 1801 Falmouth Avenue, New Hyde Park, NY dated October 31, 1999 (incorporated by reference to Exhibit 10(vi)(c) to the Company's Annual Report on Form 10-K for the year ended June 30, 2000).
- 10.9 Stock Purchase Agreement among Windham Family Limited Partnership, Peter H. Kliegman, CDC Products Corp. and Aceto Corporation (incorporated by reference to Exhibit 10(vii) to the Company's Annual Report on Form 10-K for the year ended June 30, 1999).
- 10.10 Asset Purchase Agreement among Magnum Research Corporation, CDC Products Corp., Roy Gross and Aceto Corporation (incorporated by reference to Exhibit 10 (viii) to the Company's Annual Report on Form 10-K for the year ended June 30, 2000).

## Edgar Filing: ACETO CORP - Form 10-K/A

- 10.11 Asset Purchase Agreement between Schweizerhall, Inc. and Aceto Corporation (incorporated by reference to Exhibit 10(ix) to the Company's Annual Report on Form 10-K for the year ended June 30, 2000).
- 10.12 Purchase and Sale Agreement among Schweizerhall Holding AG, Chemische Fabrik Schweizerhall, Schweizerhall, Inc., Aceto Corporation and Aceto Holding B.V., I.O. (incorporated by reference to Exhibit 2.1 to the Company's report on Form 8-K dated April 4, 2001).
- 10.13 Loan Guarantee between Aceto Corporation and subsidiaries and Deutsche Bank AG dated March 22, 2001 (incorporated by reference to Exhibit 10.13 to the Company's report on Form 10-K for the year ended June 30, 2001).
- 10.14 Credit Agreement between Aceto Corporation and subsidiaries and JPMorgan Chase Bank dated May 10, 2002 (incorporated by reference to Exhibit 10.14 to the Company's report on Form 10-K for the year ended June 30, 2002).
- 21\* Subsidiaries of the Company.
- 23\* Consent of KPMG LLP.

23

- 31.1\*\* Certification by CEO Leonard S. Schwartz pursuant to U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2\*\* Certification by CFO Douglas Roth pursuant to U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1\*\* Certification by CEO Leonard S. Schwartz pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2\*\* Certification by CFO Douglas Roth pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

-----  
\* Incorporated by reference to the Company's Form 10-K filed on September 26, 2003.

\*\* Filed herewith

24

ACETO CORPORATION AND SUBSIDIARIES

Index to Consolidated Financial Statements

## Edgar Filing: ACETO CORP - Form 10-K/A

### Independent Auditors' Report

#### Consolidated financial statements:

Consolidated balance sheets as of June 30, 2003 and 2002  
Consolidated statements of income for the years ended June 30, 2003, 2002  
and 2001  
Consolidated statements of cash flows for the years ended June 30, 2003,  
2002 and 2001  
Consolidated statements of shareholders' equity and comprehensive income  
(loss) for the years ended June 30, 2003, 2002 and 2001  
Notes to consolidated financial statements

#### Schedules:

II - Valuation and qualifying accounts

All other schedules are omitted because they are not required or the information required is given in the consolidated financial statements or notes thereto.

25

### Independent Auditors' Report

The Board of Directors and Stockholders  
Aceto Corporation:

We have audited the accompanying consolidated balance sheets of Aceto Corporation and subsidiaries as of June 30, 2003 and 2002, and the related consolidated statements of income, shareholders' equity and comprehensive income (loss), and cash flows for each of the years in the three-year period ended June 30, 2003. In connection with our audits of the consolidated financial statements, we have also audited the financial statement schedule as listed in the accompanying index. These consolidated financial statements and financial statement schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Aceto Corporation and subsidiaries as of June 30, 2003 and 2002, and the results of their

## Edgar Filing: ACETO CORP - Form 10-K/A

operations and their cash flows for each of the years in the three-year period ended June 30, 2003 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the related financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

As discussed in note 7, effective July 1, 2002, the Company adopted the provisions of Statement of Financial Accounting Standard (Statement) No. 141, "Business Combinations" and Statement No. 142, "Goodwill and Other Intangible Assets".

/s/ KPMG LLP

Melville, New York  
August 26, 2003

26

ACETO CORPORATION AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEETS  
JUNE 30, 2003 AND 2002  
(IN THOUSANDS, EXCEPT SHARE DATA)

|  | JUNE 30,<br>2003<br>---- | JUNE 30,<br>2002<br>---- |
|--|--------------------------|--------------------------|
| <b>ASSETS</b>                                |                          |                          |
| Current assets:                              |                          |                          |
| Cash and cash equivalents                    | \$ 20,263                | \$ 14,255                |
| Short-term investments                       | 877                      | 1,320                    |
| Receivables:                                 |                          |                          |
| Trade, less allowance for doubtful accounts: |                          |                          |
| 2003, \$939; 2002, \$657                     | 43,841                   | 42,417                   |
| Other  | 1,320                    | 4,266                    |
|  | -----                    | -----                    |
|  | 45,161                   | 46,683                   |
| Inventory                                    | 41,696                   | 36,271                   |
| Prepaid expenses and other current assets    | 1,015                    | 1,191                    |
| Income taxes receivable                      | 939                      | -                        |
| Deferred income tax benefit, net             | 301                      | 521                      |
| Property held for sale                       | 326                      | 483                      |
|  | -----                    | -----                    |
| Total current assets                         | 110,578                  | 100,724                  |
| Long-term notes receivable                   | 1,017                    | 691                      |
| Property and equipment:                      |                          |                          |
| Machinery and equipment                      | 1,244                    | 1,069                    |
| Leasehold improvements                       | 1,143                    | 1,143                    |
| Computer equipment and software              | 2,540                    | 1,680                    |
| Furniture and fixtures                       | 667                      | 593                      |
| Automobiles                                  | 362                      | 293                      |

Edgar Filing: ACETO CORP - Form 10-K/A

|  |           |           |
|--|-----------|-----------|
|  | -----     | -----     |
|  | 5,956     | 4,778     |
| Less accumulated depreciation and amortization | 3,681     | 2,346     |
|  | -----     | -----     |
|  | 2,275     | 2,432     |
| Goodwill, less accumulated amortization:       |           |           |
| 2003, \$677; 2002, \$1,086                     | 7,783     | 9,821     |
| Deferred income tax benefit                    | 1,107     | 1,083     |
| Other assets                                   | 759       | 952       |
|  | -----     | -----     |
| Total Assets                                   | \$123,519 | \$115,703 |
|  | =====     | =====     |

See accompanying notes to consolidated financial statements.

27

|  | June 30,<br>2003 | June 30,<br>2002 |
|--|------------------|------------------|
|  | ----             | ----             |
| (In thousands, except share data)      |                  |                  |
| LIABILITIES AND SHAREHOLDERS' EQUITY   |                  |                  |
| Current liabilities:                   |                  |                  |
| Drafts and acceptances payable         | \$ 1,315         | \$ 4,073         |
| Short-term bank loans                  | 3,286            | 7,336            |
| Current installments                   |                  |                  |
| on long-term liabilities               | -                | 272              |
| Accounts payable                       | 17,372           | 14,326           |
| Accrued merchandise purchases          | 4,048            | 4,196            |
| Accrued compensation                   | 4,117            | 2,799            |
| Accrued environmental remediation      | 1,550            | 1,284            |
| Accrued income taxes                   | -                | 1,582            |
| Other accrued expenses                 | 7,262            | 6,545            |
|  | -----            | -----            |
| Total current liabilities              | 38,950           | 42,413           |
| Shareholders' equity:                  |                  |                  |
| Common stock, \$.01 par value;         |                  |                  |
| Authorized: 20,000,000 shares          |                  |                  |
| Issued: 2003, 12,292,684 shares        |                  |                  |
| 2002, 12,292,684 shares                |                  |                  |
| Outstanding: 2003, 10,286,175 shares   |                  |                  |
| 2002, 9,825,363 shares                 | 123              | 123              |
| Capital in excess of par value         | 57,100           | 56,461           |
| Retained earnings                      | 46,142           | 40,863           |
| Treasury stock, at cost:               |                  |                  |
| 2003, 2,006,509 shares                 |                  |                  |
| 2002, 2,467,321 shares                 | (19,836)         | (24,252)         |
| Accumulated other comprehensive income | 1,040            | 95               |
|  | -----            | -----            |
| Total shareholders' equity             | 84,569           | 73,290           |
|  | -----            | -----            |

Commitments and contingencies (Note 18)

Edgar Filing: ACETO CORP - Form 10-K/A

|  |                    |                    |
|--|--------------------|--------------------|
| Total liabilities and shareholders' equity | \$123,519<br>===== | \$115,703<br>===== |
|--|--------------------|--------------------|

See accompanying notes to consolidated financial statements.

28

ACETO CORPORATION AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF INCOME  
YEARS ENDED JUNE 30, 2003, 2002 AND 2001  
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

|  | 2003<br>----      | 2002<br>----      | 2001<br>----      |
|--|-------------------|-------------------|-------------------|
| Net sales  | \$271,276         | \$229,329         | \$178,154         |
| Cost of sales  | 225,980           | 192,048           | 149,537           |
|  | -----             | -----             | -----             |
| Gross profit   | 45,296            | 37,281            | 28,617            |
| Selling, general and<br>administrative expenses                          | 32,359            | 29,945            | 22,761            |
|  | -----             | -----             | -----             |
| Operating income   | 12,937            | 7,336             | 5,856             |
| Other income (expense):  |                   |                   |                   |
| Interest expense   | (284)             | (368)             | (296)             |
| Interest and other income  | 713               | 410               | 1,226             |
|  | -----             | -----             | -----             |
|  | 429               | 42                | 930               |
|  | -----             | -----             | -----             |
| Income before income taxes and cumulative<br>effect of accounting change | 13,366            | 7,378             | 6,786             |
| Income taxes:  |                   |                   |                   |
| Federal:   |                   |                   |                   |
| Current  | 1,798             | 1,436             | 2,417             |
| Deferred   | 103               | 220               | (287)             |
| State and local:   |                   |                   |                   |
| Current  | 348               | 337               | 332               |
| Deferred   | 93                | (50)              | (50)              |
| Foreign:   |                   |                   |                   |
| Current  | 1,556             | 490               | 129               |
|  | -----             | -----             | -----             |
|  | 3,898             | 2,433             | 2,541             |
|  | -----             | -----             | -----             |
| Income before cumulative effect of<br>accounting change                  | 9,468             | 4,945             | 4,245             |
| Cumulative effect of accounting change                                   | 1,873             | -                 | -                 |
|  | -----             | -----             | -----             |
| Net income   | \$ 7,595<br>===== | \$ 4,945<br>===== | \$ 4,245<br>===== |
| Basic income per common share (a):                                       |                   |                   |                   |
| Income before accounting change  | \$ 0.96           | \$ 0.51           | \$ 0.46           |
| Cumulative effect of accounting change                                   | 0.19              | -                 | -                 |
|  | -----             | -----             | -----             |
| Net income   | \$ 0.77           | \$ 0.51           | \$ 0.46           |

Edgar Filing: ACETO CORP - Form 10-K/A

|  | =====   | =====   | =====   |
|--|---------|---------|---------|
| Diluted income per common share (a):     |         |         |         |
| Income before accounting change          | \$ 0.94 | \$ 0.50 | \$ 0.46 |
| Cumulative effect of accounting change   | 0.19    | -       | -       |
|  | -----   | -----   | -----   |
| Net income                               | \$ 0.75 | \$ 0.50 | \$ 0.46 |
|  | =====   | =====   | =====   |
| Weighted average shares outstanding (a): |         |         |         |
| Basic                                    | 9,909   | 9,779   | 9,184   |
| Diluted                                  | 10,117  | 9,833   | 9,222   |

(a) The number of shares outstanding and the per share information have been adjusted for a 3-for-2 split of the common stock, paid January 2, 2003.

See accompanying notes to consolidated financial statements.

29

ACETO CORPORATION AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
YEARS ENDED JUNE 30, 2003, 2002 AND 2001  
(IN THOUSANDS)

|   | 2003     | 2002     | 2001     |
|---|----------|----------|----------|
|   | ----     | ----     | ----     |
| Operating activities:   |          |          |          |
| Net income  | \$ 7,595 | \$ 4,945 | \$4,240  |
| Adjustments to reconcile net income to net cash provided by operating activities: |          |          |          |
| Cumulative effect of accounting change  | 1,873    | -        |          |
| Depreciation and amortization   | 1,038    | 1,629    | 900      |
| Gain on sale of assets  | (291)    | (3)      |          |
| Provision for doubtful accounts   | 446      | 566      | 300      |
| Foreign currency translation adjustment   | 945      | 859      | (76)     |
| Deferred tax provision (benefit)  | 196      | 170      | (33)     |
| Income tax benefit on exercise of stock options                                   | 1,589    | 10       |          |
| Changes in assets and liabilities, net of effect of the acquisitions:             |          |          |          |
| Investments - trading securities  | 74       | 37       | (5)      |
| Trade accounts receivable   | (1,870)  | (4,698)  | 57       |
| Other receivables   | 2,937    | (1,036)  | 14       |
| Income taxes receivable   | (939)    | -        |          |
| Inventory   | (5,425)  | (137)    | 6,280    |
| Prepaid expenses and other current assets   | 176      | (505)    | 38       |
| Other assets  | 69       | (158)    | (2)      |
| Drafts & acceptances payable  | (2,758)  | 2,540    | 1,060    |
| Accounts payable  | 3,046    | 3,797    | 1,450    |
| Accrued merchandise purchases   | (148)    | 2,570    | (10,390) |
| Accrued compensation  | 1,318    | (114)    | (29)     |
| Accrued environmental remediation   | 266      | (8)      | (2)      |
| Accrued income taxes  | (1,582)  | 1,063    | (84)     |
| Other accrued expenses and long term liabilities                                  | 577      | 3,953    | (22)     |
|   | -----    | -----    | -----    |



Edgar Filing: ACETO CORP - Form 10-K/A

|  |          |          |          |
|--|----------|----------|----------|
| Net cash provided by operating activities  | 9,132    | 15,480   | 2,400    |
|  | -----    | -----    | -----    |
| Investing activities:  |          |          |          |
| Proceeds from maturation of held-to-maturity investments                                       | 369      | -        | 8,118    |
| Payments received on notes receivable  | 96       | 88       | 8        |
| Purchases of property and equipment  | (590)    | (640)    | (1,300)  |
| Proceeds from sale of property, net of closing costs   | 173      | 12       |          |
| Acquisition of businesses, net of cash acquired  | -        | (563)    | 1,200    |
| Payments for additional inventory recorded in goodwill   | -        | (2,639)  |          |
| Proceeds from settlement of certain acquired accounts receivable balances recorded in goodwill | -        | 1,571    |          |
|  | -----    | -----    | -----    |
| Net cash provided by (used in) investing activities  | 48       | (2,171)  | 8,098    |
|  | -----    | -----    | -----    |
| Financing activities:  |          |          |          |
| Payments of short-term bank loans  | (4,050)  | (1,528)  | (10,000) |
| Payments of current installments on long-term liabilities                                      | (272)    | -        |          |
| Payments of cash dividends   | (2,316)  | (2,088)  | (1,930)  |
| Payments of long-term liabilities  | -        | (796)    | (530)    |
| Payments of notes payable - acquisition  | -        | (2,313)  | (2,310)  |
| Proceeds from exercise of stock options  | 3,269    | 239      | 330      |
| Payments for purchases of treasury stock   | (39)     | (121)    | (1,640)  |
| Issuance of treasury stock to employees  | 236      | 243      | 180      |
|  | -----    | -----    | -----    |
| Net cash used in financing activities  | (3,172)  | (6,364)  | (6,000)  |
|  | -----    | -----    | -----    |
| Net increase in cash   | 6,008    | 6,945    | 4,498    |
| Cash at beginning of year  | 14,255   | 7,310    | 2,810    |
|  | -----    | -----    | -----    |
| Cash at end of year  | \$20,263 | \$14,255 | \$7,310  |
|  | =====    | =====    | =====    |

See accompanying notes to consolidated financial statements.

ACETO CORPORATION AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY AND COMPREHENSIVE INCOME (LOSS)  
(In thousands, except share data)

| Common Stock  |                    | Capital in Excess of Par Value | Retained Earnings | Treasury Shares |
|---------------|--------------------|--------------------------------|-------------------|-----------------|
| Shares Issued | Par Value (\$ .01) |                                |                   |                 |
| -----         | -----              | -----                          | -----             | -----           |

Edgar Filing: ACETO CORP - Form 10-K/A

|   |            |       |          |          |             |    |
|---|------------|-------|----------|----------|-------------|----|
| Balance at June 30, 2000                          | 12,292,684 | \$123 | \$57,021 | \$35,697 | (2,966,573) | \$ |
| Net income  | -          | -     | -        | 4,245    | -           | -  |
| Other comprehensive income (loss):                |            |       |          |          |             |    |
| Foreign currency translation adjustments          | -          | -     | -        | -        | -           | -  |
| Comprehensive income                              |            |       |          |          |             |    |
| Stock issued pursuant to employee incentive plans | -          | -     | (12)     | -        | 20,479      |    |
| Cash dividends:                                   |            |       |          |          |             |    |
| Common stock (\$0.21 per share)                   | -          | -     | -        | (1,936)  | -           |    |
| Exercise of stock options                         | -          | -     | 14       | -        | 23,250      |    |
| Tax benefit from exercise of stock option plans   | -          | -     | 9        | -        | -           |    |
| Treasury stock purchases                          | -          | -     | -        | -        | (174,739)   |    |
| Lapsed stock options                              | -          | -     | 80       | -        | -           |    |
| Shares issued in connection with acquisition      | -          | -     | (729)    | -        | 600,000     |    |
| <hr/>   |            |       |          |          |             |    |
| Balance at June 30, 2001                          | 12,292,684 | 123   | 56,383   | 38,006   | (2,497,583) |    |
| Net income  | -          | -     | -        | 4,945    | -           |    |
| Other comprehensive income (loss):                |            |       |          |          |             |    |
| Foreign currency translation adjustments          | -          | -     | -        | -        | -           |    |
| Comprehensive income                              |            |       |          |          |             |    |
| Stock issued pursuant to employee incentive plans | -          | -     | 9        | -        | 23,762      |    |
| Cash dividends:                                   |            |       |          |          |             |    |
| Common stock (\$0.21 per share)                   | -          | -     | -        | (2,088)  | -           |    |
| Exercise of stock options                         | -          | -     | (22)     | -        | 18,300      |    |
| Tax benefit from exercise of stock option plans   | -          | -     | 10       | -        | -           |    |
| Treasury stock purchases                          | -          | -     | -        | -        | (11,800)    |    |
| Lapsed stock options                              | -          | -     | 81       | -        | -           |    |
| <hr/>   |            |       |          |          |             |    |
| Balance at June 30, 2002                          | 12,292,684 | 123   | 56,461   | 40,863   | (2,467,321) |    |
| Net income  | -          | -     | -        | 7,595    | -           |    |
| Other comprehensive income (loss):                |            |       |          |          |             |    |
| Foreign currency translation adjustments          | -          | -     | -        | -        | -           |    |
| Comprehensive income                              |            |       |          |          |             |    |
| Stock issued pursuant to employee incentive plans | -          | -     | 61       | -        | 17,733      |    |
| Cash dividends:                                   |            |       |          |          |             |    |
| Common stock (\$0.23 per share)                   | -          | -     | -        | (2,316)  | -           |    |
| Exercise of stock options                         | -          | -     | (1,040)  | -        | 446,879     |    |
| Tax benefit from exercise of stock option plans   | -          | -     | 1,589    | -        | -           |    |
| Treasury stock purchases                          | -          | -     | -        | -        | (3,800)     |    |
| Lapsed stock options                              | -          | -     | 29       | -        | -           |    |
| <hr/>   |            |       |          |          |             |    |
| Balance at June 30, 2003                          | 12,292,684 | \$123 | \$57,100 | \$46,142 | (2,006,509) | \$ |

See accompanying notes to consolidated financial statements.

ACETO CORPORATION AND SUBSIDIARIES  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  
YEARS ENDED JUNE 30, 2003, 2002 AND 2001

(In thousands, except per share amounts)

(1) DESCRIPTION OF BUSINESS

Aceto Corporation and subsidiaries (the Company) is primarily engaged in the marketing, sale and distribution of pharmaceutical, fine and industrial chemicals used principally in the agricultural, color producing, pharmaceutical, nutraceutical and surface coating industries. Most of the chemicals distributed by the Company are purchased abroad. The Company's customers are located throughout the United States and other countries including Mexico, Brazil, Malaysia, Australia, Singapore, Thailand, Canada, Germany, France, the United Kingdom and The Netherlands.

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions are eliminated in consolidation.

USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates.

CASH EQUIVALENTS

The Company considers all highly liquid debt instruments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents at June 30, 2003 include U.S. Treasury bills in the amount of \$2,996. There were no cash equivalents at June 30, 2002.

INVESTMENTS

The Company classifies investments in marketable securities as trading, available-for-sale or held-to-maturity at the time of purchase and periodically re-evaluates such classifications. Trading securities are carried at fair value, with unrealized holding gains and losses included in earnings. Held-to-maturity securities are recorded at cost and are adjusted for the amortization or accretion of premiums or discounts over the life of the related security. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of accumulated other comprehensive income (loss) until realized. In determining realized gains and losses, the cost of securities sold is based on the specific identification method. Interest and dividends on the investments are accrued at the balance sheet date.

INVENTORY

Inventories are valued at the lower of cost or market. Cost is determined using the first in, first out (FIFO) basis.

ENVIRONMENTAL REMEDIATION

The Company accrues for losses associated with environmental remediation obligations when such losses are probable and can be reasonably estimated. Such

## Edgar Filing: ACETO CORP - Form 10-K/A

accruals are adjusted as further information develops or circumstances change.

### COMMON STOCK SPLIT

On December 5, 2002, the Board of Directors of the Company declared a 3-for-2 split of the Company's common stock in the form of a 50 percent common stock dividend that was paid January 2, 2003, to shareholders of record on December 18, 2002. The

32

Company transferred \$33 to common stock from capital in excess of par value, representing the aggregate par value of the shares issued under the stock split.

All references to the number of common shares and the per common share amounts have been restated to give retroactive effect to the above stock split for all periods presented.

### STOCK OPTIONS

The Company applies Accounting Principles Board Opinion, "Accounting for Stock Issued to Employees" (APB 25), and related interpretations for stock options and other stock-based awards while disclosing pro forma net income and earnings per share as if the fair value method had been applied in accordance with Statement of Financial Accounting Standards (SFAS) No. 123, "Accounting for Stock-Based Compensation."

The Company applies the intrinsic value method as outlined in Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees", and related interpretations in accounting for stock options and share units granted under these programs. Under the intrinsic value method, no compensation expense is recognized if the exercise price of the Company's employee stock options equals the market price of the underlying stock on the date of grant. Since the Company has issued all stock grants at market value, no compensation cost has been recognized. Statement of Financial Accounting Standard ("SFAS") No. 123, "Accounting for Stock-Based Compensation", requires that the Company provide pro forma information regarding net income and net income per common share as if compensation cost for the Company's stock option programs had been determined in accordance with the fair value method prescribed therein. The Company adopted the disclosure portion of SFAS No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure" requiring quarterly SFAS No. 123 pro forma disclosure. The following table illustrates the effect on net income and income per common share as if the Company had measured the compensation cost for the Company's stock option programs under the fair value method in each period presented.

|   | 2003<br>----     | 2002<br>----     | 2001<br>----     |
|---|------------------|------------------|------------------|
| Net income, as reported   | \$7,595          | \$4,945          | \$4,245          |
| Deduct: Total stock-based<br>employee compensation expense<br>determined under fair value<br>method for all awards, net of<br>related tax effects | (761)<br>-----   | (213)<br>-----   | (226)<br>-----   |
| Net income - pro forma  | \$6,834<br>===== | \$4,732<br>===== | \$4,019<br>===== |
| Net income per common share:  |                  |                  |                  |
| Basic - as reported (a):  | \$ 0.77          | \$ 0.51          | \$ 0.46          |
| Basic - pro forma   | \$ 0.69          | \$ 0.48          | \$ 0.44          |

## Edgar Filing: ACETO CORP - Form 10-K/A

|                            |         |         |         |
|----------------------------|---------|---------|---------|
| Diluted - as reported (a): | \$ 0.75 | \$ 0.50 | \$ 0.46 |
| Diluted - pro forma        | \$ 0.68 | \$ 0.48 | \$ 0.44 |

(a) Retroactively adjusted to reflect a 3-for-2 stock dividend distributed on January 2, 2003 to common stockholders of records as of the close of business December 18, 2002.

### REVENUE RECOGNITION

The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss to the customer. Such revenues do not involve difficult, subjective, or complex judgments. The Company does not offer product warranties to its customers.

### RESEARCH AND DEVELOPMENT COSTS

Research and development costs are expensed as incurred and are included in cost of sales. Such costs were approximately \$71, \$269 and \$121 for the years ended June 30, 2003, 2002 and 2001, respectively.

33

### NET INCOME PER COMMON SHARE

Net income per common share amounts (basic EPS) were computed by dividing net income by the weighted average number of common shares outstanding and excluded any potential dilution. Net income per common share amounts, assuming dilution (diluted EPS), were computed by reflecting potential dilution from the exercise of stock options.

The net income per common share amounts for each of the periods presented are based on the weighted average number of common shares outstanding, adjusted to reflect the 3-for-2 common stock split paid on January 2, 2003.

### INCOME TAXES

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

### PROPERTY AND EQUIPMENT

Property and equipment are stated at cost and are depreciated using straight line, sum-of-the-years digits and declining balance methods. The estimated useful lives are as follows:

|                                 | Years |
|---------------------------------|-------|
|                                 | ----- |
| Machinery and equipment         | 10    |
| Computer equipment and software | 3-5   |
| Furniture and fixtures          | 10    |
| Automobiles                     | 3     |

Leasehold improvements are amortized over the shorter of the life of the asset or the lease term.

Depreciation and amortization of property and equipment amounted to \$795, \$738, and \$550 for the years ended June 30, 2003, 2002, and 2001, respectively.

## Edgar Filing: ACETO CORP - Form 10-K/A

### GOODWILL

In July 2001, the Financial Accounting Standards Board ("FASB") issued SFAS No. 141, "Business Combinations" (SFAS 141), and SFAS No. 142, "Goodwill and Other Intangible Assets" (SFAS 142). SFAS No. 141 specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill. SFAS No. 142 requires that goodwill and intangible assets with indefinite useful lives no longer be amortized, but instead be tested for impairment at least annually in accordance with the provisions of SFAS No. 142. SFAS No. 142 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives and reviewed for impairment in accordance with SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets". The Company adopted the provisions of SFAS 141 and SFAS 142 as of July 1, 2002.

As required by SFAS 142, the Company completed its transitional impairment testing of intangible assets. Under SFAS 142, goodwill impairment exists if the net book value of a reporting unit exceeds its estimated fair value. The impairment testing is performed in two steps: (i) the Company determines impairment by comparing the fair value of a reporting unit with its carrying value, and (ii) if there is an impairment, the Company measures the amount of impairment loss by comparing the implied fair value of goodwill with the carrying amount of that goodwill.

As of July 1, 2002, with the assistance of a third-party valuation firm, the Company finalized the testing of goodwill. The Company estimated the fair value of its reporting units by using a combination of discounted cash flow analyses and comparisons with the market values of similar publicly-traded companies. As a result of the impairment tests, the Company recorded a goodwill impairment charge of \$1,873 related to a business in the Institutional Sanitary Supply segment, which has been included as a cumulative effect of an accounting change in the accompanying consolidated statement of income for the year ended June 30, 2003 (note 7).

34

Also required by SFAS 142, on an annual basis, the Company tests goodwill and other intangible assets for impairment. To determine the fair value of these intangible assets, there are many assumptions and estimates used that directly impact the results of testing. In making these assumptions and estimates, the Company uses industry accepted valuation models and set criteria that are reviewed and approved by various levels of management, and the Company estimates the fair value of its reporting units by using a combination of discounted cash flow analyses and comparisons with the market values of similar publicly-traded companies. Additionally, the Company utilizes the assistance of a third-party valuation firm, as necessary, to help evaluate recorded goodwill.

**IMPAIRMENT OF LONG-LIVED ASSETS AND LONG-LIVED ASSETS TO BE DISPOSED OF**  
Effective July 1, 2002, the Company adopted SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets", which establishes accounting and reporting standards for the impairment or disposal of long-lived assets. SFAS No. 144 removes goodwill from its scope and retains the requirements of SFAS No. 121 regarding the recognition of impairment losses on long-lived assets held for use.

Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability of assets held for sale is measured by comparing the carrying amount of the assets to their estimated fair market value. If such assets are

## Edgar Filing: ACETO CORP - Form 10-K/A

considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

Property held for sale, which includes land and land improvements, is stated at cost. Impairment, if any, is recognized if the estimated fair value less costs to sell is lower than the carrying value.

### ACCOUNTING FOR DERIVATIVES AND HEDGING ACTIVITIES

The Company accounts for derivatives and hedging activities under the provisions of SFAS 133, "Accounting for Derivative Instruments and Hedging Activities", which establishes accounting and reporting guidelines for derivative instruments and hedging activities. SFAS 133 requires the recognition of all derivative financial instruments as either assets or liabilities in the statement of financial condition and measurement of those instruments at fair value. Changes in the fair values of those derivatives are reported in earnings or other comprehensive income depending on the designation of the derivative and whether it qualifies for hedge accounting. The accounting for gains and losses associated with changes in the fair value of a derivative and the effect on the consolidated financial statements depends on its hedge designation and whether the hedge is highly effective in achieving offsetting changes in the fair value or cash flows of the asset or liability hedged. Under the provisions of SFAS 133, the method that is used for assessing the effectiveness of a hedging derivative, as well as the measurement approach for determining the ineffective aspects of the hedge, is established at the inception of the hedged instrument.

Designation is established at the inception of a derivative, but redesignation is permitted. For derivatives designated as fair value hedges, changes in fair value are recognized in earnings. If the fair value hedge is fully effective, the change in fair value of the hedged item attributable to the hedged risk, is adjusted to fair value and is recognized in earnings.

The Company operates internationally, therefore its earnings, cash flows and financial positions are exposed to foreign currency risk from foreign currency denominated receivables and payables. These items are denominated in various foreign currencies, including Euros, British Pounds, Japanese Yen, Singapore Dollars and Chinese Yuan Renminbi.

Management believes it is prudent to minimize the risk caused by foreign currency fluctuation. Management minimizes the risk by hedging the majority of all foreign currency obligations by purchasing future foreign currency contracts (futures) with one of its financial institutions. Futures are traded on regulated U.S. and

international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Since futures are purchased for the exact amount of foreign currency needed to pay for specific purchase orders, the Company feels that it eliminates all risks relating to foreign currency fluctuation. The Company takes delivery of all futures, which have been designated as fair value hedges under SFAS 133, to pay suppliers in the appropriate currency. The difference between the fair value and nominal amounts of the foreign currency contracts and the related commitments have been recorded as an asset with a corresponding liability in the accompanying consolidated balance sheet at June 30, 2003 in the amount of \$99. The hedge contracts flow through cost of goods sold in the consolidated statement of income as inventory is sold. Senior management and members of the financial department continually monitor foreign currency risks and the use of this derivative instrument.

## Edgar Filing: ACETO CORP - Form 10-K/A

### FOREIGN CURRENCY

The functional currency of the Company's foreign subsidiaries is the applicable local currency. The translation of the applicable foreign currencies into U.S. dollars is performed for balance sheet accounts using current exchange rates in effect at the balance sheet date and for revenue and expense accounts and cash flows using average rates of exchange prevailing during the year. Adjustments resulting from the translation of foreign currency financial statements are accumulated in a separate component of stockholders' equity.

### RECLASSIFICATIONS

Certain reclassifications have been made to the prior consolidated financial statements to conform to the current presentation.

### (3) BUSINESS ACQUISITIONS

On March 26, 2001, the Company acquired (i) the distribution business of the Schweizerhall Pharma division of Schweizerhall Holding AG, a Switzerland corporation and (ii) certain assets relating to the Pharmaceutical Ingredients business of Schweizerhall, Inc., a New Jersey corporation, and a wholly owned subsidiary of Schweizerhall Holding AG (collectively, "Schweizerhall Pharma").

Schweizerhall Pharma's distribution business is an international pharmaceutical distribution business with offices located in: Hamburg, Germany; Wormerveer, The Netherlands (a suburb of Amsterdam); Paris, France; Piscataway, New Jersey; Singapore; Mumbai, India; and Hong Kong. Its principal activities are the supply of Active Pharmaceutical Ingredients and Advanced Intermediates.

The total purchase price for the Schweizerhall Pharma acquisition was \$25,980. This amount consisted of 600 restricted shares of the Company's Common Stock, the assumption of \$8,966 of Schweizerhall Holding AG debt, \$5,973 in cash, the issuance of notes of \$4,626 and acquisition costs of \$1,240. The quoted market price of the Common Stock on March 26, 2001 of \$8.625 per share, was used to approximate the fair value of the 600 shares issued, which amounted to \$5,175. In connection with the closing of the acquisition the Company assumed certain debt of Schweizerhall Holding AG in excess of the amount of the purchase price. As a result, at closing Schweizerhall Holding AG paid \$7,162 to the Company. Subsequent to March 31, 2001 the Company paid Schweizerhall Holding AG \$8,987 and was released from a portion of the debt assumed at closing.

The notes payable of \$4,626 issued at closing bear interest at 3%. Principal and interest are payable monthly. Monthly principal payments are determined by the lesser of the outstanding principal balance or the book value of certain inventory (as defined in the note agreement) sold in the preceding month. These notes were paid in full during the year ended June 30, 2002.

The acquisition was accounted for as a purchase and, accordingly, the cost of the acquisition was allocated to the assets acquired, based upon their estimated fair values at the date of acquisition. The results of operations of Schweizerhall Pharma have been included in the accompanying consolidated statement of income from the date of acquisition. During the quarter ended September 30, 2001, the Company received \$1,571 from the previous owners of Schweizerhall Pharma in settlement of certain accounts receivable balances, which was recorded as a reduction to goodwill.

The excess of cost over the fair value of assets acquired (goodwill) amounted to \$6,393. Prior to the adoption of SFAS 142 (Note 7) effective July 1, 2002, goodwill was amortized on a straight-line basis over a period of twenty years. Amortization of goodwill related to the Schweizerhall Pharma acquisition



## Edgar Filing: ACETO CORP - Form 10-K/A

amounted to \$326 for the year ended June 30, 2002. In accordance with SFAS 142, there was no amortization of goodwill for the year ended June 30, 2003. The non-competition agreements are valued at \$300 and are being amortized over three years, the term of the non-competition agreements. An intangible asset related to customer contracts is valued at \$600 and is being amortized over five years. The allocation of the purchase price has been completed. During fiscal 2003, the Company reduced goodwill in the amount of \$165 as a result of the utilization of certain net operating loss carry-forwards that were previously reserved for in purchase accounting.

The purchase agreement provides for two additional payments pertaining to inventory and tax savings. An additional payment for \$2,639 was made in May 2002 in connection with inventory which has been allocated to the additional inventory purchased and which has been included in the cash paid of \$5,973. Any payments made in connection with the tax savings adjustment will be recorded as additional goodwill.

In connection with the March 26, 2001 Schweizerhall Pharma acquisition, the Company recorded liabilities for employee severance and for operating lease payments as a result of exit plans formulated as of the acquisition date. The severance accrual relates to involuntary termination of administration and middle management personnel from the acquired operations. During fiscal 2002, the Company refined its estimation of severance to include certain additional administrative and middle management employees. The operating lease payment relates to equipment and facilities leases assumed by the Company. Additional goodwill recorded by the Company amounted to \$519 and \$44 for employee severance and operating lease payments, respectively, as a result of the Company's exit plans. Amounts accrued represent management's best estimate of the cost to exit the equipment and facilities leases, including lease payments and termination costs, net of recoverable amounts. All exit plan liabilities were paid during fiscal 2002.

The following unaudited condensed pro forma financial information of the Company for the year ended June 30, 2001 includes the consolidated results of operations of the Company as if the acquisition of Schweizerhall had occurred on July 1, 2000:

|                                    | (unaudited)<br>2001<br>---- |
|------------------------------------|-----------------------------|
| Net revenue                        | \$238,963                   |
| Net earnings                       | 1,334                       |
| Net earnings per diluted share (1) | 0.14                        |

(1) The per share information has been adjusted for a 3-for-2 split of the common stock, paid January 2, 2003.

The unaudited condensed pro forma financial information includes adjustments to the Company's historical results to reflect incremental amortization of goodwill and the non-competition agreement and customer contracts, reduced interest income generated from cash that was used for acquisition, additional interest expense and income tax adjustments. The unaudited pro forma consolidated financial statements do not purport to be indicative of the operating results of financial position that would have been achieved had the acquisition taken place on the date indicated or the results that may be obtained in the future.

#### (4) INVESTMENTS

A summary of trading securities, classified as short-term, follows:

| June 30, 2003 | June 30, 2002 |
|---------------|---------------|
| -----         | -----         |

Edgar Filing: ACETO CORP - Form 10-K/A

|                      | Fair Value<br>----- | Cost<br>Basis<br>----- | Fair Value<br>----- | Cost<br>Basis<br>----- |
|----------------------|---------------------|------------------------|---------------------|------------------------|
| Corporate securities | \$ 877              | \$ 594                 | \$ 951              | \$ 594                 |

The change in the net unrealized holding gains (losses) on trading securities was \$(74), \$(37) and \$ 53 for fiscal 2003, 2002 and 2001, respectively.

37

There were no held-to-maturity securities as of June 30, 2003, as the Company's held-to-maturity securities matured in March 2003 resulting in proceeds of \$369. A summary of held-to-maturity securities as of June 30, 2002 follows:

|                              | June 30, 2002<br>-----             |                                       |  |                        |
|------------------------------|------------------------------------|---------------------------------------|--|------------------------|
|                              | Amortized<br>Cost or Cost<br>----- | Gross<br>Unrealized<br>Gains<br>----- | Gross<br>Unrealized<br>Losses<br>----- | Fair<br>Value<br>----- |
| Held-to-maturity securities: |                                    |                                       |  |                        |
| Short-term investments:      |                                    |                                       |  |                        |
| Municipal obligations        | \$369                              | \$ -                                  | \$ -                                   | \$369                  |

During fiscal 2001, the Company sold \$7,900 of held-to-maturity securities before their maturity date and realized a gain of \$40. The proceeds from the sale of these securities were used in the acquisition of the Schweizerhall Pharma business (note 3).

(5) INVENTORY

Inventory consists of the following:

|                 | June 30<br>----- |               |
|-----------------|------------------|---------------|
|                 | 2003<br>-----    | 2002<br>----- |
| Finished goods  | \$41,221         | \$35,897      |
| Work in process | 157              | 134           |
| Raw materials   | 318              | 240           |
|                 | -----            | -----         |
| Total           | \$41,696         | \$36,271      |
|                 | =====            | =====         |

(6) NOTES RECEIVABLE

The Company currently holds seven notes receivable with outstanding balances aggregating \$1,129 and \$813 at June 30, 2003 and 2002, respectively, which have arisen from sales of property. The notes are either secured by a first mortgage on the real property sold or collateralized by a security interest in the asset sold. The notes range in length from four to nineteen years and pay interest at a fixed rate. The range of fixed rates on the notes is 4.0% to 9.5%. Included in current assets are notes receivable due within one year totaling \$113 and \$122 at June 30, 2003 and 2002, respectively.

(7) BUSINESS COMBINATIONS AND GOODWILL AND OTHER INTANGIBLE ASSETS

The Company has adopted the provisions of SFAS 141 and 142 as of July 1, 2002 (note 2). The Company has evaluated its existing goodwill that was acquired in prior purchase business combinations and has determined that no adjustment or reclassification to intangible assets at July 1, 2002 is required in order to conform to the new criteria in SFAS 141 for recognition apart from goodwill.

## Edgar Filing: ACETO CORP - Form 10-K/A

As of June 30, 2003 and June 30, 2002, the Company had intangible assets subject to amortization of \$1,020 and \$1,287, respectively, and related accumulated amortization of \$608 and \$586, respectively, which pertained to customer lists and covenants not to compete and have been included in other assets on the accompanying consolidated balance sheets. Amortization expense for intangible assets subject to amortization amounted to \$241 and \$352 for the year ended June 30, 2003 and 2002, respectively. The estimated aggregate amortization expense for intangible assets subject to amortization for each of the succeeding years ended June 30, 2004 through June 30, 2006 are as follows: 2004: \$202; 2005: \$120; 2006: \$90.

As required by SFAS 142, the Company performed impairment tests on goodwill as of July 1, 2002. As a result of the impairment tests, the Company recorded a goodwill impairment charge of \$1,873 which has been included as a cumulative effect of an accounting change in the accompanying consolidated statement of income for the year ended June 30, 2003. Under SFAS 142, goodwill impairment exists if the net book value of a reporting unit exceeds its estimated fair value. The Company estimated the fair value of its reporting units by using a combination of discounted cash flow analyses and comparisons with the market values of similar publicly-traded companies.

The Company's \$1,873 impairment charge was related to the impairment of the goodwill associated with CDC Products Corp. ("CDC"). CDC was acquired by the Company during

38

fiscal 1999. Due to an increase in competition from local sanitary supply companies in the markets CDC operates in, recent operating profits and cash flows were lower than expected. Based on that trend, the earnings forecast for the next five years was revised. During the year ended June 30, 2003, a goodwill impairment charge of \$1,873 was recognized in the CDC reporting unit. The fair value of that reporting unit was determined by using a combination of discounted cash flow analyses and comparisons with the market values of similar publicly-traded companies. The revised fair value of this unit was allocated to the assets and liabilities of the business unit to arrive at an implied fair value of goodwill, based upon known facts and circumstances, as if the acquisition occurred currently.

The following table displays a roll forward of the carrying amount of goodwill for the year ended June 30, 2003, by business segment:

|  | Health Sciences<br>----- | Institutional<br>Sanitary<br>Supplies &<br>Other<br>----- | Consolidated<br>Totals<br>----- |
|--|--------------------------|---|---------------------------------|
| Balance at 6/30/02                           | \$7,003                  | \$2,818   | \$9,821                         |
| Adjustment for tax savings from acquired NOL | (165)                    | -   | (165)                           |
| Impairment losses                            | -                        | (1,873)   | (1,873)                         |
| Balance at 6/30/03                           | \$6,838                  | \$ 945  | \$7,783                         |

Edgar Filing: ACETO CORP - Form 10-K/A

=====

=====

=====

39

Goodwill amortization for the years ended June 30, 2002 and 2001 was \$539 and \$275, respectively. The following table shows the results of operations as if SFAS No. 142 was applied to prior periods:

|  | Year Ended |         |         |
|--|------------|---------|---------|
|  | June 30,   |         |         |
|  | 2003       | 2002    | 2001    |
|  | ----       | ----    | ----    |
| Income before cumulative effect<br>of accounting change, as reported | \$9,468    | \$4,945 | \$4,245 |
| Add back: Goodwill amortization,<br>net of tax                       | -          | 400     | 205     |
|  | -----      | -----   | -----   |
| Adjusted income before cumulative<br>effect of accounting change     | \$9,468    | \$5,345 | \$4,450 |
|  | =====      | =====   | =====   |
| Basic income per common share:                                       |            |         |         |
| Income before cumulative effect<br>of accounting change, as reported | \$ 0.96    | \$ 0.51 | \$ 0.46 |
| Goodwill amortization,<br>net of tax                                 | -          | 0.04    | 0.02    |
|  | -----      | -----   | -----   |
| Adjusted income before cumulative<br>effect of accounting change     | \$ 0.96    | \$ 0.55 | \$ 0.48 |
|  | =====      | =====   | =====   |
| Diluted income per common share:                                     |            |         |         |
| Income before cumulative effect<br>of accounting change, as reported | \$ 0.94    | \$ 0.50 | \$ 0.46 |
| Goodwill amortization,<br>net of tax                                 | -          | 0.04    | 0.02    |
|  | -----      | -----   | -----   |
| Adjusted income before cumulative<br>effect accounting change        | \$ 0.94    | \$ 0.54 | \$ 0.48 |
|  | =====      | =====   | =====   |

(8) ENVIRONMENTAL REMEDIATION

During fiscal 1993 the Company announced the closing of its manufacturing subsidiary located in Carlstadt, New Jersey. At the same time an environmental consultant was engaged by the Company to determine the extent of contamination on the site and develop a plan of remediation. Based on the initial estimates from the consultant a liability of \$1,500 was established in fiscal 1993. During fiscal 1997, after additional testing was completed, the Company received a revised estimate from the consultant and an additional liability of \$800 was recorded. At June 30, 2002, the remaining liability was \$1,284.

During fiscal 2003, based on continued monitoring of the contamination on the site and the current proposed plan of remediation, the Company received a revised estimate from the consultant, which estimated that the remaining costs of the remediation could be an amount between \$1,550 and \$3,200. During fiscal 2003, the Company recorded an additional liability in the amount of \$266 resulting in a liability as of June 30, 2003 in the amount of \$1,550. However, these matters, if resolved in a manner different from those assumed in current estimates could have a material adverse effect on financial condition, operating

## Edgar Filing: ACETO CORP - Form 10-K/A

results and cash flows when resolved in a future reporting period. Other than the remediation associated with the Carlstadt, New Jersey facility, the Company is not aware of any material environmental liabilities.

### (9) FINANCING ARRANGEMENTS

In May 2002, the Company entered into a \$15,000 revolving credit agreement with a financial institution which expires June 30, 2004. Under the credit agreement, the Company may obtain credit through direct borrowings and letters of credit. The obligations of the Company under the credit agreement are guaranteed by certain of the Company's subsidiaries and is secured by sixty-five percent of the capital of certain non-domestic subsidiaries which the Company owns. There is no borrowing base on the credit agreement. Interest under the credit agreement is at LIBOR plus 1.50%, which was 2.62% and 3.34% at June 30, 2003 and 2002, respectively. The credit agreement contains several financial covenants requiring, among other things, minimum levels of debt service and tangible net worth. The Company is also subject to certain restrictive debt covenants including liens, limitations on indebtedness, guarantees, sale of assets, sales of receivables, and loans and investments. In March 2003, the Company obtained a waiver to its credit agreement which allowed it to guarantee an obligation of one of its wholly-owned subsidiaries to a vendor under a distribution agreement. The Company was in compliance with all covenants at June 30, 2003.

40

At June 30, 2003 and 2002, the Company had available lines of credit with foreign financial institutions totaling \$16,588 and \$14,385, respectively. The Company entered into the agreements with foreign banks as part of the Schweizerhall Pharma acquisition. The Company has issued a cross corporate guarantee to the foreign banks. Short term loans under these agreements bear interest at LIBOR plus 0.75%, which was 1.87% and 2.59% at June 30, 2003 and 2002, respectively. The Company is not subject to any financial covenants under these arrangements.

Under the above financing arrangements, the Company had short-term bank loans of \$3,286 and \$1,199 in letters of credit leaving an unused facility of \$27,103 at June 30, 2003. For June 30, 2002 the Company utilized \$7,336 in short-term loans and \$1,544 in letters of credit leaving an unused facility of \$20,505. The weighted average interest rate on short-term loans outstanding for the years ended June 30, 2003 and 2002, was 4.80% and 4.70% respectively.

### (10) NET INCOME PER COMMON SHARE

A reconciliation between the numerators and denominators of the basic and diluted income per share computation for net income follows:

|  | 2003    | 2002    | 2001    |
|--|---------|---------|---------|
|  | ----    | ----    | ----    |
| Income before cumulative effect of accounting change | \$9,468 | \$4,945 | \$4,245 |
| Cumulative effect of accounting change               | 1,873   | -       | -       |
|  | -----   | -----   | -----   |
| Net income available for common shareholders         | \$7,595 | \$4,945 | \$4,245 |
|  | =====   | =====   | =====   |
| Weighted average common shares (basic) (a)           | 9,909   | 9,779   | 9,184   |
| Effect of dilutive securities:                       |         |         |         |
| Stock options (a)                                    | 208     | 54      | 38      |
|  | -----   | -----   | -----   |

Edgar Filing: ACETO CORP - Form 10-K/A

|   |                  |                  |                  |
|---|------------------|------------------|------------------|
| Weighted average common and potential common shares outstanding (diluted) (a) | 10,117<br>=====  | 9,833<br>=====   | 9,222<br>=====   |
| Basic income per common share(a):   |                  |                  |                  |
| Income before cumulative effect of accounting change                          | \$ 0.96          | \$ 0.51          | \$ 0.46          |
| Cumulative effect of accounting change  | 0.19<br>-----    | -<br>-----       | -<br>-----       |
| Net income  | \$ 0.77<br>===== | \$ 0.51<br>===== | \$ 0.46<br>===== |
| Diluted income per common share(a):   |                  |                  |                  |
| Income before cumulative effect of accounting change                          | \$ 0.94          | \$ 0.50          | \$ 0.46          |
| Cumulative effect of accounting change  | 0.19<br>-----    | -<br>-----       | -<br>-----       |
| Net income  | \$ 0.75<br>===== | \$ 0.50<br>===== | \$ 0.46<br>===== |

(a) Share and per share information have been adjusted for a 3-for-2 split of the common stock, paid January 2, 2003.

In fiscal 2003, 2002, and 2001, employee stock options of 240, 353, and 600, respectively, were not included in the diluted income per common share calculation because their effect would have been anti-dilutive.

(11) STOCK BASED COMPENSATION PLANS

In September 2002, the Company adopted the Aceto Corporation 2002 Stock Option Plan (2002 Plan), which was ratified by the Company's shareholders at the December 2002 Annual Meeting. Under the 2002 Plan, options or restricted stock to purchase up to 750 shares of the Company's common stock may be granted by the Company to officers, directors, employees and agents of the Company. The exercise price per share shall be not less than the fair market value of Aceto common stock on the date of grant and

41

each option may not become exercisable less than six months from the date it is granted. Restricted stock may be granted to an eligible participant in lieu of a portion of any annual cash bonus earned by such participant. Such award may have a premium in shares greater than the portion of bonus paid in restricted stock. The award vests ratably over a period of years as determined by the Board. The premium vests when the award is fully vested, provided that the participant is in the employ of the Company when vesting occurs.

In December 2002, the Company granted 470 options to employees and directors under the Plan at an exercise price of \$9.63 which was equal to the fair market value of the common stock on the date of grant. 397 of these options vest in full on the fifth anniversary of the date of grant subject, however, to acceleration beginning after one year from the date of grant, if the publicly traded price of the Company's common stock exceeds certain levels for a certain number of trading days. The remaining 73 options vest on the first anniversary of the date of grant. The options expire no later than ten years from the date of grant. As of June 30, 2003, there were 281 shares of common stock available

## Edgar Filing: ACETO CORP - Form 10-K/A

for grant as either options or restricted stock under the 2002 Plan.

In December 1998, the Company adopted the Aceto Corporation 1998 Omnibus Equity Award Plan (1998 Plan). In accordance with the 1998 Plan the Company's Board of Directors (Board) may grant up to 750 shares of common stock in the form of stock options or restricted stock to eligible participants. The exercise price per share, determined by the Board, for options granted cannot be less than the fair market value of the stock on the date of grant. The options vest as determined by the Board and expire no later than ten years from the date of grant. Restricted stock may be granted to an eligible participant in lieu of a portion of any annual cash bonus earned by such participant. Such award may have a premium in shares greater than the portion of bonus paid in restricted stock. The award vests ratably over a period of years as determined by the Board. The premium vests when the award is fully vested, provided that the participant is in the employ of the Company when vesting occurs. Under the 1998 Plan, there were 67 and 72 shares of common stock available for grant as either options or restricted stock at June 30, 2003 and 2002, respectively.

Under the terms of the Company's 1980 Stock Option Plan (1980 Plan), options may be issued to officers and key employees. The exercise price per share can be greater or less than the market value of the stock on the date of grant. The options vest either immediately or over a period of years as determined by the Board of Directors and expire no later than five or ten years from the date they are fully vested. Under the 1980 Plan, options to purchase 668 and 632 shares of common stock were available for grant at June 30, 2003 and 2002, respectively. The Board does not intend to issue additional options from this Plan.

The following tabulations summarize the shares of common stock under option for all plans at June 30, 2003, 2002 and 2001, and the activity with respect to options for the respective years then ended:

|                          | Shares<br>subject to<br>option<br>----- | Weighted average<br>exercise price<br>per share<br>----- |
|--------------------------|---|--|
| Balance at June 30, 2000 | 1,002                                   | \$ 6.63  |
| Granted                  | 106                                     | 6.42   |
| Exercised                | (35)                                    | 5.21   |
| Forfeited/lapsed         | (104)                                   | 6.69   |
| -----                    |   |  |
| Balance at June 30, 2001 | 969                                     | \$ 6.66  |
| Granted                  | 182                                     | 6.56   |
| Exercised                | (27)                                    | 5.27   |
| Forfeited                | (93)                                    | 6.33   |
| -----                    |   |  |
| Balance at June 30, 2002 | 1,031                                   | \$ 6.71  |
| Granted                  | 470                                     | 9.63   |
| Exercised                | (485)                                   | 6.98   |
| Forfeited/lapsed         | (53)                                    | 6.66   |
| -----                    |   |  |
| Balance at June 30, 2003 | 963                                     | \$ 7.96  |

Options exercisable at June 30, 2003, 2002 and 2001 were 359, 674 and 537, respectively. The weighted average exercise price for options exercisable at June 30, 2003, 2002 and 2001 was \$6.48, \$6.93 and \$6.72, respectively. At June 30, 2003,

outstanding options had expiration dates ranging from December 10, 2008 to

## Edgar Filing: ACETO CORP - Form 10-K/A

December 31, 2015.

Under the 1980 Plan, during the period options become exercisable, compensation is charged to operations for the excess of fair market value over the option price at the date of grant. Such charges to operations were \$-0-, \$-0- and \$13 in fiscal 2003, 2002 and 2001, respectively. Under the 2002 Plan and the 1998 Plan, compensation is recorded for the value of restricted stock granted. There were 19, 36 and 29 shares of restricted stock granted during fiscal 2003, 2002 and 2001, respectively. Such charges to operations were \$225, \$214 and \$199 in fiscal 2003, 2002 and 2001, respectively.

Summarized information about stock options outstanding and exercisable at June 30, 2003 was as follows:

| Exercise Price Range | Outstanding      |                 | Exercisable      |                  |                  |
|----------------------|------------------|-----------------|------------------|------------------|------------------|
|                      | Number of Shares | Average Life(1) | Average Price(2) | Number of Shares | Average Price(2) |
| \$6.00 - 6.99        | 439              | 9.0             | \$6.14           | 304              | \$6.20           |
| 7.00 - 8.50          | 55               | 5.6             | 8.28             | 55               | 8.28             |
| 8.51 - 9.63          | 469              | 9.5             | 9.63             | -                | -                |

(1) Weighted average contractual life remaining, in years.

(2) Weighted average exercise price.

The per share weighted average fair value of stock options granted during 2003, 2002 and 2001 was \$5.51, \$2.18 and \$2.22, respectively, on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions:

|      | Date of Grant | Expected volatility(%) | Expected life (years) | Risk-free interest rate(%) | Dividend yield(%) |
|------|---------------|------------------------|-----------------------|----------------------------|-------------------|
| 2003 | 12/05/02      | 40                     | 7.5                   | 3.79                       | 2.22              |
| 2002 | 12/06/01      | 20                     | 7.5                   | 5.46                       | 3.25              |
| 2001 | 10/25/00      | 20                     | 7.5                   | 5.68                       | 3.08              |
|      | 12/17/00      | 20                     | 7.5                   | 5.31                       | 3.29              |
|      | 3/27/01       | 20                     | 7.5                   | 5.01                       | 3.48              |
|      | 4/05/01       | 20                     | 7.5                   | 4.97                       | 3.53              |
|      | 5/08/01       | 20                     | 7.5                   | 5.24                       | 3.45              |

### (12) INTEREST AND OTHER INCOME

Interest and other income earned during fiscal 2003, 2002 and 2001 were comprised of the following:

|                                | 2003   | 2002   | 2001     |
|--------------------------------|--------|--------|----------|
| Dividends                      | \$ 139 | \$ 196 | \$ 128   |
| Interest                       | 458    | 212    | 468      |
| Net gain (loss) on investments | (74)   | (37)   | 53       |
| Royalty income                 | -      | -      | 354      |
| Miscellaneous                  | 190    | 39     | 223      |
|                                | -----  | -----  | -----    |
|                                | \$ 713 | \$ 410 | \$ 1,226 |
|                                | =====  | =====  | =====    |



## Edgar Filing: ACETO CORP - Form 10-K/A

### (13) INCOME TAXES

The components of income before the provision for income taxes are as follows:

|                     | 2003     | 2002     | 2001     |
|---------------------|----------|----------|----------|
|                     | ----     | ----     | ----     |
| Domestic operations | \$ 4,912 | \$ 4,922 | \$ 6,503 |
| Foreign operations  | 8,454    | 2,456    | 283      |
|                     | -----    | -----    | -----    |
|                     | \$13,366 | \$ 7,378 | \$ 6,786 |
|                     | =====    | =====    | =====    |

The tax effects of temporary differences that give rise to the deferred tax assets and liabilities at June 30, 2003 and 2002 are presented below:

43

|  | 2003    | 2002    |
|--|---------|---------|
|  | -----   | -----   |
| Deferred tax assets:   |         |         |
| Accrued environmental remediation liabilities not currently deductible | \$ 588  | \$ 502  |
| Accrued retirement plan  | 396     | 384     |
| Accrued compensation   | 133     | 391     |
| Additional costs inventoried for tax purposes                          | 101     | 120     |
| Allowance for doubtful accounts receivable                             | 219     | 235     |
| Differences in depreciation of property and equipment                  | 92      | 73      |
| Differences in amortization of intangible assets                       | 64      | 45      |
| Accrued professional services  | 15      | 39      |
| Net operating loss carry forwards                                      | 5,537   | 1,870   |
|  | -----   | -----   |
| Total gross deferred tax assets  | 7,145   | 3,659   |
| Valuation allowances   | (5,537) | (1,870) |
|  | -----   | -----   |
| Total net deferred tax assets  | 1,608   | 1,789   |
|  | -----   | -----   |
| Deferred tax liabilities:  |         |         |
| Unrealized gain on investments   | (107)   | (139)   |
| Goodwill   | (93)    | (46)    |
|  | -----   | -----   |
| Total gross deferred tax liabilities                                   | (200)   | (185)   |
|  | -----   | -----   |
| Net deferred tax assets  | \$1,408 | \$1,604 |
|  | =====   | =====   |

The net change in the total valuation allowance for the year ended June 30, 2003 was an increase of \$3,667 resulting from a valuation allowance recorded for net operating losses in certain foreign jurisdictions. A valuation allowance is provided when it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The Company has established valuation allowances primarily for net operating loss carryforwards in certain foreign countries. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the

## Edgar Filing: ACETO CORP - Form 10-K/A

periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. In order to fully realize the net deferred tax assets recognized at June 30, 2003, the Company will need to generate future domestic taxable income of approximately \$4,819. Domestic taxable income for fiscal 2003 and 2002 was approximately \$5,288 and \$4,734, respectively.

Based upon the level of historical taxable income and projections for taxable income over the periods which the deferred tax assets are deductible, management believes it is more likely than not the Company will realize the benefits of these deductible differences. There can be no assurance, however, that the Company will generate any earnings or any specific level of continuing earnings in the future. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced.

Deferred taxes have not been provided on undistributed earnings of foreign subsidiaries since substantially all of these earnings are expected to be permanently reinvested in foreign operations. Determination of the amount of unrecognized deferred U.S. income tax liabilities and potential foreign tax credits is not practical to calculate because of the complexity of this hypothetical calculation.

Reconciliation of the statutory Federal income tax rate and the effective tax rate for the fiscal years ended June 30, 2003, 2002 and 2001 follows:

44

|  | 2003  | 2002  | 2001  |
|--|-------|-------|-------|
|  | ----  | ----  | ----  |
| Federal statutory tax rate                                     | 34.0% | 34.0% | 34.0% |
| State and local taxes, net<br>of Federal income tax<br>benefit | 2.2   | 2.6   | 2.7   |
| Foreign tax rate differential                                  | (9.9) | (4.9) | 0.5   |
| Other  | 2.9   | 1.3   | 0.2   |
|  | ----  | ----  | ----  |
| Effective tax rate   | 29.2% | 33.0% | 37.4% |
|  | ====  | ====  | ====  |

At June 30, 2003, the Company had net operating loss carry forwards for foreign income tax purposes of approximately \$19,500 which are available to offset future foreign taxable income, if any, of which \$4,767 will expire from the year 2004 through the year 2007 and others which have no expiration date.

#### (14) Supplemental Cash Flow Information

Cash paid for interest and income taxes during fiscal 2003, 2002 and 2001 was as follows:

|                   | 2003   | 2002   | 2001   |
|-------------------|--------|--------|--------|
|                   | ----   | ----   | ----   |
| Interest paid     | \$ 560 | \$ 586 | \$ 248 |
| Income taxes paid | 4,234  | 1,405  | 3,642  |

In connection with the acquisition of Schweizerhall Pharma in March 2001, the Company assumed debt of \$8,966, issued \$4,626 of notes payable and issued 600 common shares from treasury stock at an average cost of \$9.84 each.

## Edgar Filing: ACETO CORP - Form 10-K/A

In connection with the settlement of arbitration (note 19) in the fourth quarter of fiscal 2001, the Company recorded a reduction to long term liabilities and goodwill for \$360.

### (15) RETIREMENT PLANS

The Company has retirement plans in which employees are eligible to participate. The Company's annual contribution per employee, which is at management's discretion, is based on a percentage of the employee's compensation. The Company's provisions for contributions amounted to \$1,017, \$895 and \$864 in fiscal 2003, 2002 and 2001, respectively.

### (16) SEGMENT INFORMATION

The Company, prior to fiscal 2002, was organized into six reportable segments, organized by product. Effective for the fiscal year ended June 30, 2002, the two segments formerly known as Industrial Chemicals and Organic Intermediates & Colorants have been combined into a segment called Chemicals and Colorants. Effective for the fiscal year ended June 30, 2003, the two segments formerly known as Pharmaceuticals, Biochemicals & Nutritionals and Pharmaceutical Intermediates & Custom Manufacturing have been combined into a segment called Health Sciences. The amounts previously reported for the former segments have been combined accordingly.

Therefore, the Company's four reportable segments, organized by product are as follows:

(1) Agrochemicals, whose products include herbicides, fungicides and insecticides, as well as a sprout inhibitor for potatoes, (2) Chemicals and Colorants, whose products include a variety of specialty chemicals used in plastics, resins, adhesives, coatings, food, flava, fragrance, cosmetics, metal finishing, electronics and many other areas in addition to dye and pigment intermediates used in the color-producing industries like textiles, inks, paper and coatings, as well as intermediates used in the production of agrochemicals; (3) Health Sciences, which include the active ingredients for generic pharmaceuticals, vitamins and nutritional supplements, as well as products used in preparation of pharmaceuticals, primarily by major innovative drug companies and (4) Institutional Sanitary Supplies & Other, whose products include cleaning solutions, fragrances and deodorants used by commercial and industrial establishments. The Company does not allocate assets by segment. The Company's chief decision maker evaluates performance of the segments based on gross profit.

45

|                                 | Agro-<br>chemicals | Chemicals<br>& Colorants | Health Sciences | Institutional<br>Sanitary<br>Supplies<br>& Other | Consolid<br>Total |
|---------------------------------|--------------------|--------------------------|-----------------|--|-------------------|
| 2003                            |                    |                          |                 |  |                   |
| ----                            |                    |                          |                 |  |                   |
| Net sales                       | \$14,356           | 91,579                   | 159,858         | 5,483  | \$271,2           |
| Gross Profit                    | \$ 4,123           | 12,673                   | 29,569          | 2,418  | \$ 48,7           |
| Unallocated<br>cost of sales(1) |                    |                          |                 |  | 3,4               |
|                                 |                    |                          |                 |  | -----             |
| Net gross<br>profit             |                    |                          |                 |  | \$ 45,2           |
|                                 |                    |                          |                 |  | =====             |
| 2002                            |                    |                          |                 |  |                   |

Edgar Filing: ACETO CORP - Form 10-K/A

|                                 |          |        |         |       |         |       |
|---------------------------------|----------|--------|---------|-------|---------|-------|
| -----                           |          |        |         |       |         |       |
| Net sales                       | \$13,540 | 90,494 | 120,021 | 5,274 | \$229,3 |       |
| Gross Profit                    | \$ 4,215 | 13,502 | 20,240  | 2,294 | \$ 40,2 |       |
| Unallocated<br>cost of sales(1) |          |        |         |       |         | 2,9   |
|                                 |          |        |         |       |         | ----- |
| Net gross<br>profit             |          |        |         |       | \$ 37,2 | ===== |
| 2001                            |          |        |         |       |         |       |
| -----                           |          |        |         |       |         |       |
| Net sales                       | \$13,133 | 97,902 | 61,137  | 5,982 | \$178,1 |       |
| Gross Profit                    | \$ 4,943 | 15,529 | 11,948  | 1,562 | \$ 33,9 |       |
| Unallocated<br>cost of sales(1) |          |        |         |       |         | 5,3   |
|                                 |          |        |         |       |         | ----- |
| Net gross<br>profit             |          |        |         |       | \$ 28,6 | ===== |

(1) Represents freight and storage costs that are not allocated to a segment.

46

Net sales and long-lived assets by location as of and for the years ended June 30, 2003, 2002 and 2001 were as follows:

|                 | Net Sales |           |           | Gross Profit |          |          | Long-Lived Assets |       |
|-----------------|-----------|-----------|-----------|--------------|----------|----------|-------------------|-------|
|                 | 2003      | 2002      | 2001      | 2003         | 2002     | 2001     | 2003              | 2001  |
|                 | ----      | ----      | ----      | ----         | ----     | ----     | ----              | ----  |
| United States   | \$178,597 | \$163,886 | \$161,741 | \$30,030     | \$26,798 | \$26,356 | \$1,457           | \$1,  |
| Germany         | 35,219    | 25,729    | 5,926     | 5,671        | 4,494    | 1,005    | 556               |       |
| The Netherlands | 7,568     | 5,876     | 1,576     | 1,955        | 1,194    | 359      | 113               |       |
| France          | 10,032    | 12,323    | 3,645     | 1,558        | 1,612    | 357      | 61                |       |
| Asia-Pacific    | 39,860    | 21,515    | 5,266     | 6,082        | 3,183    | 540      | 88                |       |
|                 | -----     | -----     | -----     | -----        | -----    | -----    | -----             | ----- |
| Total           | \$271,276 | \$229,329 | \$178,154 | \$45,296     | \$37,281 | \$28,617 | \$2,275           | \$2,  |
|                 | =====     | =====     | =====     | =====        | =====    | =====    | =====             | ===== |

47

(17) FINANCIAL INSTRUMENTS

DERIVATIVE FINANCIAL INSTRUMENTS

At June 30, 2003 and 2002 the Company had future foreign exchange contracts that have a notional amount of \$3,431 and \$28, respectively. The contracts have varying maturities extending to November 2003. At June 30, 2003 and 2002 the

## Edgar Filing: ACETO CORP - Form 10-K/A

Company had not hedged open purchase commitments of approximately \$51 and \$1,185, respectively. For fiscal 2003, 2002 and 2001, gains and losses on foreign currency transactions, including terminated hedges that occurred prior to the transaction date, were not material.

The Company is exposed to credit losses in the event of non-performance by the financial institutions, who are the counter parties, on its future foreign currency contracts. The Company anticipates, however, that the financial institutions will be able to fully satisfy their obligations under the contracts. The Company does not obtain collateral to support financial instruments, but monitors the credit standing of the financial institution.

### OFF-BALANCE SHEET RISK

Commercial letters of credit are issued by the Company during the ordinary course of business through major domestic banks as requested by certain suppliers. The Company had open letters of credit of approximately \$1,199 and \$1,544 as of June 30, 2003 and 2002, respectively. The terms of these letters of credit are all less than one year. No material loss is anticipated due to non-performance by the counter parties to these agreements.

### FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair value of foreign currency contracts (used for hedging purposes) was estimated by obtaining quotes from brokers and the difference between the fair value and contract value was \$99. The difference between the fair value of long-term notes receivable and their carrying value at both June 30, 2003 and 2002 was not material. The fair value of the Company's notes receivable was based upon current rates offered for similar financial instruments to the Company.

### BUSINESS AND CREDIT CONCENTRATION

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of trade receivables. The Company's customers are dispersed across many industries and are located throughout the United States as well as in Mexico, Brazil, Malaysia, France, Canada, Germany, Australia, the United Kingdom, The Netherlands and others. The Company estimates an allowance for doubtful accounts based upon the credit worthiness of its customers as well as general economic conditions. Consequently, an adverse change in those factors could affect the Company's estimate of this allowance. The Company as a policy does not require collateral from its customers. At June 30, 2003, five customers accounted for 17% of net trade accounts receivable. At June 30, 2002, five customers accounted for 18% of net trade accounts receivable concentration. At June 30, 2003 and 2002, the top five customers accounted for 20% and 16%, respectively, of net sales.

No single product accounted for as much as 10% of net sales in fiscal 2003, 2002 or 2001. One supplier accounted for 10% of purchases in fiscal 2003. No supplier accounted for as much as 10% of total purchases in fiscal 2002 or 2001.

48

During the fiscal years ended June 30, 2003 and 2002, approximately 59% and 60%, respectively, of the Company's purchases of chemicals came from Asia and approximately 29% and 25%, respectively, from Europe.

The Company maintains operations located outside of the United States. Net assets located in Europe and Asia approximate \$10,238 and \$10,378, respectively at June 30, 2003.

(18) COMMITMENTS AND CONTINGENCIES

## Edgar Filing: ACETO CORP - Form 10-K/A

(a) A subsidiary of the Company markets certain agricultural chemicals which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the Environmental Protection Agency (EPA) to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate the generation of new test data to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of two such task force groups and may be required to make additional payments in the future.

(b) The Company and its subsidiaries are subject to various claims which have arisen in the normal course of business. The impact of the final resolution of these matters on the Company's results of operations or liquidity in a particular reporting period is not known. Management is of the opinion, however, that the ultimate outcome of such matters will not have a material adverse effect upon the Company's financial condition or liquidity.

(c) In 2002 a vendor made allegations that the Company breached a purchase contract. As a result, the Company recorded a liability during fiscal 2003 of \$450. At June 30, 2003 the remaining liability is \$450. In the opinion of management, based on its knowledge of the facts and discussions with counsel, the ultimate outcome of this allegation is not expected to have a material adverse effect on the Company's consolidated financial position, although the resolution in any reporting period of this matter could have a significant impact on the Company's results of operations for that period.

(d) The Company currently leases office facilities in the United States, The Netherlands, Germany, France, China and Singapore. In addition, a domestic subsidiary leases a manufacturing facility under an operating lease expiring December 2009. At June 30, 2003, the future minimum lease payments in the aggregate and for each of the five succeeding years are as follows:

| Fiscal year | Amount   |
|-------------|----------|
| -----       | -----    |
| 2004        | \$ 1,418 |
| 2005        | 1,350    |
| 2006        | 1,316    |
| 2007        | 1,212    |
| 2008        | 1,136    |
| Thereafter  | 2,941    |
|             | -----    |
|             | \$ 9,373 |
|             | =====    |

Total rental expense amounted to approximately \$1,444, \$1,471 and \$983 for fiscal 2003, 2002 and 2001, respectively.

(e) In February 2001, the Company entered into a three-year contract with a vendor, commencing September 1, 2001, to purchase specified amounts of a certain product to be sold to a customer during the life of the contract. At June 30, 2003, future minimum purchases required to be

made under the contract in the aggregate and for each of the five succeeding years are as follows:

## Edgar Filing: ACETO CORP - Form 10-K/A

| Fiscal Year | Amount   |
|-------------|----------|
| 2004        | \$12,491 |
| 2005        | 835      |
| 2006        | -        |
| 2007        | -        |
| 2008        | -        |
| Thereafter  | -        |
|             | -----    |
|             | \$13,326 |
|             | =====    |

Total purchases under the contract amounted to approximately \$0, \$3,024 and \$0 for fiscal 2003, 2002 and 2001, respectively.

### (19) SETTLEMENT OF ARBITRATION

During the fourth quarter of fiscal 2001, the Company received a decision from the arbitrators regarding the claims made by the Company and previous owner of CDC. The decision denied all claims made against the Company by the previous owner and reduced the purchase price of CDC by \$360. As a result the Company recorded the reduction of the outstanding liability owed to the previous owner by \$360 and recorded a reduction to goodwill for the same amount. The liability was paid in full as of August 2002.

### (20) IMPACT OF NEW ACCOUNTING PRONOUNCEMENTS

In July 2002, the FASB issued No. 146, "Accounting for Costs Associated with Exit or Disposal Activities". SFAS 146 will spread out the reporting of expenses related to restructurings initiated after 2002, because commitment to a plan to exit an activity or dispose of long-lived assets will no longer be enough to record a liability for the anticipated costs. Instead, companies will record exit and disposal costs when they are "incurred" and can be measured at fair value, and they will subsequently adjust the recorded liability for changes in estimated cash flows. The Company adopted the provisions of SFAS 146 as of January 1, 2003. The adoption of this statement did not have a significant impact on the Company's consolidated financial statements.

In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure" (SFAS 148). SFAS 148 provides alternative methods of transition for a voluntary change to the fair value method of accounting for stock-based employee compensation as originally defined by SFAS No. 123, "Accounting for Stock-Based Compensation." Additionally, SFAS 148 amends the disclosure requirements of SFAS No. 123 to require prominent disclosure in both the annual and interim financial statements about the method of accounting for stock-based compensation and the effect of the method used on reported results. The transitional requirements of SFAS 148 are effective for all financial statements for fiscal years ending after December 15, 2002. The Company adopted the disclosure portion of this statement for the fiscal quarter ended March 31, 2003. The application of the disclosure portion of this standard had no impact on the Company's consolidated financial position or results of operations. The FASB recently indicated that it will require stock-based employee compensation to be recorded as a charge to earnings pursuant to a standard on which it is currently deliberating. The FASB anticipates issuing an Exposure Draft in the fourth quarter of 2003 and a final statement in the second quarter of 2004. The Company will continue to monitor the FASB's progress on the issuance of this standard as well as evaluate the Company's position with respect to current guidance.

In April 2003, the FASB issued SFAS No. 149, "Amendment of Statement 133 on

## Edgar Filing: ACETO CORP - Form 10-K/A

Derivative Instruments and Hedging Activities", which amends and clarifies accounting for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities under SFAS No. 133. SFAS No. 149 is effective for contracts entered into or modified after June 30, 2003 and for hedging relationships designated after June 30, 2003. The Company does not believe that the adoption of SFAS No. 149 will have a material impact on its consolidated financial statements.

In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain Financial Instruments with Characteristics of both Liability and Equity", which establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liability and equity in its statement of financial position. SFAS No. 150 is effective for new or modified financial instruments beginning July 1, 2003 and for existing instruments beginning August 1, 2003. The Company does not believe that the adoption of SFAS No. 150 will have a material impact on its consolidated financial statements.

In November 2002, the FASB issued Interpretation No. 45, "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness to Others" ("Int. No. 45"), which addresses the disclosure to be made by a guarantor in its interim and annual financial statements about its obligations under guarantees. Int. No. 45 also requires the guarantor to recognize a liability for the non-contingent component of the guarantee, which is the obligation to stand ready to perform in the event that specified triggering events or conditions occur. The recognition and measurement provisions of Int. No. 45 are effective for all guarantees entered into or modified after December 31, 2002. The Company has not entered into any such guarantees and therefore the adoption of this standard did not impact the Company's consolidated financial statements.

In January 2003, the FASB issued Interpretation No. 46, "Consolidation of Variable Interest Entities," ("Int. No. 46") an interpretation of ARB No. 51. Int. No. 46 addresses consolidation by business enterprises of variable interest entities. Int. No. 46 applies immediately to variable interest entities created after January 31, 2003 and to variable interest entities in which an enterprise obtains an interest after that date. Int. No. 46 applies in the first year or interim period beginning after June 15, 2003 to variable interest entities in which an enterprise holds a variable interest that it acquired before February 1, 2003. The Company is in the process of determining the impact of implementing Int. No. 46 on its consolidated financial statements.

### (21) UNAUDITED QUARTERLY FINANCIAL DATA

The following is a summary of the unaudited quarterly results of operations for the years ended June 30, 2003 and 2002.

#### QUARTERLY FINANCIAL DATA (Unaudited) (In thousands except per share amounts)

|  | Year Ended June 30, 2003 |               |               |               |
|--|--------------------------|---------------|---------------|---------------|
|  | Quarter Ended            |               |               |               |
|  | Sept. 30, 2002           | Dec. 31, 2002 | Mar. 31, 2003 | June 30, 2003 |
|  | -----                    | -----         | -----         | -----         |
| Net sales  | \$68,022                 | \$64,633      | \$70,561      | \$68,060      |
| Gross profit   | 11,245                   | 11,006        | 11,794        | 11,251        |
| Income before<br>cumulative<br>effect of<br>accounting<br>change | 2,323                    | 2,328         | 2,411         | 2,406         |
| Net income   | 450 (2)                  | 2,328         | 2,411         | 2,406         |



Edgar Filing: ACETO CORP - Form 10-K/A

|   |          |      |      |      |
|---|----------|------|------|------|
| Income before cumulative effect of accounting change per common share - diluted (1) | 0.24     | 0.23 | 0.24 | 0.23 |
| Net income per common share - diluted (1) (2)                                       | 0.05 (2) | 0.23 | 0.24 | 0.23 |

51

Year Ended June 30, 2002  
Quarter Ended

|   | Sept. 30, 2001 | Dec. 31, 2001 | Mar. 31, 2002 | June 30, 2002 |
|---|----------------|---------------|---------------|---------------|
|   | -----          | -----         | -----         | -----         |
| Net sales                                 | \$47,641       | \$55,365      | \$61,594      | \$64,729      |
| Gross profit                              | 7,246          | 9,466         | 9,757         | 10,812        |
| Net income                                | 535            | 1,243         | 1,523         | 1,644         |
| Net income per common share - diluted (1) | 0.05           | 0.13          | 0.15          | 0.17          |

(1) Adjusted for a 3-for-2 stock split of the common stock, paid January 2, 2003.

(2) Reflects a charge of \$1,873 for a cumulative effect of an accounting change resulting from an impairment of goodwill which was determined to be required upon the Company's adoption of SFAS 142.

Net income per common share calculation for each of the quarters is based on weighted average number of shares outstanding in each period. Therefore, the sum of the quarters in a year does not necessarily equal the year's net income per common share.

52

Schedule II

ACETO CORPORATION AND SUBSIDIARIES

VALUATION AND QUALIFYING ACCOUNTS

For the Years Ended June 30, 2003, 2002 and 2001  
(dollars in thousands)

| Description | Balance at beginning of year | Charged to costs and expenses | Charged to other accounts | Deductions | Balance at end of year |
|-------------|------------------------------|-------------------------------|---------------------------|------------|------------------------|
|-------------|------------------------------|-------------------------------|---------------------------|------------|------------------------|

## Edgar Filing: ACETO CORP - Form 10-K/A

|                                 |        |        |   |            |        |
|---------------------------------|--------|--------|---|------------|--------|
| Year ended June 30, 2003:       |        |        |   |            |        |
| Allowance for doubtful accounts | \$ 657 | \$ 446 | - | \$ 164 (a) | \$ 939 |
|                                 | ===    | ===    |   | ===        | ===    |
| Year ended June 30, 2002:       |        |        |   |            |        |
| Allowance for doubtful accounts | \$ 316 | \$ 566 | - | \$ 225 (a) | \$ 657 |
|                                 | ===    | ===    |   | ===        | ===    |
| Year ended June 30, 2001:       |        |        |   |            |        |
| Allowance for doubtful accounts | \$ 239 | \$ 307 | - | \$ 230 (a) | \$ 316 |
|                                 | ===    | ===    |   | ===        | ===    |

(a) Specific accounts written off as uncollectible, net of recoveries.

53

### EXHIBIT INDEX

- 3.1 Restated Certificate of Incorporation (incorporated by reference to Exhibit 4(a)(iii) to Registration Statement No. 2-70623 on Form S-8 (S-8 2-70623)).
- 3.2 Certificate of Amendment dated November 21, 1985 to Restated Certificate of Incorporation (incorporated by reference to Exhibit 3(ii) to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1986).
- 3.3 By-laws (incorporated by reference to Exhibit 3(iii)(c) to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1998).
- 10.1 Profit Sharing Plan, as amended and restated effective July 1, 1989 (incorporated by reference to Exhibit 10(iii)(a) to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1995).
- 10.2 401(k) Plan, effective August 1, 1997, (incorporated by reference to Exhibit 10 (iii) to the Company's Annual Report on Form 10-K for the year ended June 30, 1998).
- 10.3 Supplemental Executive Retirement Plan, effective June 30, 1985, as amended and restated, effective July 1, 1992 (incorporated by reference to Exhibit 10(iv)(a) to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1993).
- 10.4 Aceto Corporation Stock Option Plan (as Amended and Restated effective as of September 19, 1990) (and as further Amended effective June 9, 1992) (incorporated by reference to Exhibit 10(v)(b) to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1992).
- 10.5 1998 Aceto Corporation Omnibus Equity Award Plan (incorporated by

## Edgar Filing: ACETO CORP - Form 10-K/A

reference to Exhibit 10(v) to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1999).

- 10.6 Lease between Aceto Corporation and M. Parisi & Son Construction Co., Inc. for office space at One Hollow Lane, Lake Success, NY dated April 28, 2000 (incorporated by reference to Exhibit 10(vi) to the Company's Annual Report Form 10-K for the fiscal year ended June 30, 2000).
- 10.7 Lease between Aceto Corporation and M. Parisi & Son Construction Co., Inc. for office space at One Hollow Lane, Lake Success, NY dated April 28, 2000 (incorporated by reference to Exhibit

54

10(vi) (b) to the Company's Annual Report on Form 10-K for the year ended June 30, 2000).

- 10.8 Lease between CDC Products Corp. and Seaboard Estates for manufacturing and office space at 1801 Falmouth Avenue, New Hyde Park, NY dated October 31, 1999 (incorporated by reference to Exhibit 10(vi) (c) to the Company's Annual Report on Form 10-K for the year ended June 30, 2000).
- 10.9 Stock Purchase Agreement among Windham Family Limited Partnership, Peter H. Kliegman, CDC Products Corp. and Aceto Corporation (incorporated by reference to Exhibit 10(vii) to the Company's Annual Report on Form 10-K for the year ended June 30, 1999).
- 10.10 Asset Purchase Agreement among Magnum Research Corporation, CDC Products Corp., Roy Gross and Aceto Corporation (incorporated by reference to Exhibit 10 (viii) to the Company's Annual Report on Form 10-K for the year ended June 30, 2000).
- 10.11 Asset Purchase Agreement between Schweizerhall, Inc. and Aceto Corporation (incorporated by reference to Exhibit 10(ix) to the Company's Annual Report on Form 10-K for the year ended June 30, 2000).
- 10.12 Purchase and Sale Agreement among Schweizerhall Holding AG, Chemische Fabrik Schweizerhall, Schweizerhall, Inc., Aceto Corporation and Aceto Holding B.V., I.O. (incorporated by reference to Exhibit 2.1 to the Company's report on Form 8-K dated April 4, 2001).
- 10.13 Loan Guarantee between Aceto Corporation and subsidiaries and Deutsche Bank AG dated March 22, 2001 (incorporated by reference to Exhibit 10.13 to the Company's report on Form 10-K for the year ended June 30, 2001).
- 10.14 Credit Agreement between Aceto Corporation and Subsidiaries and JPMorgan Chase Bank dated May 10, 2002 (incorporated by reference to Exhibit 10.14 to the Company's report on Form 10-K for the year ended June 30, 2002).
- 21\* Subsidiaries of the Company.
- 23\* Consent of KPMG LLP.
- 31.1\*\* Certification by CEO Leonard S. Schwartz pursuant to U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes- Oxley Act of 2002.

Edgar Filing: ACETO CORP - Form 10-K/A

31.2\*\* Certification by CFO Douglas Roth pursuant to U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1\*\* Certification by CEO Leonard S. Schwartz pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

55

32.2\*\* Certification by CFO Douglas Roth pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

\* Incorporated by reference to the Company's Form 10-K filed on September 26, 2003.

\*\* Filed herewith

56

SIGNATURES

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ACETO CORPORATION

By /s/ Leonard S. Schwartz

-----

Leonard S. Schwartz  
Chairman, President  
and Chief Executive Officer

Date: October 21, 2003

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.

| Signatures | Title | Date |
|------------|-------|------|
| -----      | ----- | ---- |

Edgar Filing: ACETO CORP - Form 10-K/A

|   |   |          |
|---|---|----------|
| /s/ Leonard S. Schwartz<br>-----<br>Leonard S. Schwartz | Chairman, President and<br>Chief Executive Officer<br>(Principal Executive Officer)                   | 10-21-03 |
| /s/ Douglas Roth<br>-----<br>Douglas Roth               | Secretary/Treasurer and<br>Chief Financial Officer<br>(Principal Financial and<br>Accounting Officer) | 10-21-03 |
| /s/ Stanley Fischer<br>-----<br>Stanley Fischer         | Director  | 10-21-03 |
| /s/ Samuel I. Hendler<br>-----<br>Samuel I. Hendler     | Director  | 10-21-03 |
| /s/ Robert Wiesen<br>-----<br>Robert Wiesen             | Director  | 10-21-03 |
| /s/ Ira S. Kallem<br>-----<br>Ira S. Kallem             | Director  | 10-21-03 |
| /s/ Albert L. Eilender<br>-----<br>Albert L. Eilender   | Director  | 10-21-03 |
| /s/ Hans C. Noetzli<br>-----<br>Hans C. Noetzli         | Director  | 10-21-03 |